

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

BMJ Open

Investigating Mental Defeat in Patients with Chronic Pain: Protocol for a Longitudinal Experience Sampling Study

Journal:	BMJ Open	
Manuscript ID	bmjopen-2022-066577	
Article Type:	Protocol	
Date Submitted by the Author:	12-Jul-2022	
Complete List of Authors:	Gillett, Jenna; University of Warwick, Psychology Karadag, Paige; University of Warwick, Psychology Themelis, Kristy; University of Warwick, Psychology Li, Yu-Mei; Bielefeld University, Psychology Lemola, Sakari ; Bielefeld University, Psychology Balasubramanian, Shyam; University Hospitals Coventry and Warwickshire NHS Trust Singh, Swaran; University of Warwick Warwick Medical School, Mental Health and Wellbeing Tang, Nicole; University of Warwick, Psychology	
Keywords:	PAIN MANAGEMENT, MENTAL HEALTH, STATISTICS & RESEARCH METHODS	
Note: The following files were submitted by the author for peer review, but cannot be converted to PDF. You must view these files (e.g. movies) online.		

actiwatch_video_supplementary material.mp4

SCHOLARONE[™] Manuscripts

BMJ Open

TITLE: Investigating Mental Defeat in Patients with Chronic Pain: Protocol for a Longitudinal Experience Sampling Study AUTHORS: Jenna L Gillett (PhD Researcher)^{1*}, Paige Karadag (Research Assistant)^{1*}, Kristy Themelis (Post-Doctoral Research Fellow)¹, Yu-Mei Li (Post-Doctoral Research Fellow)², Sakari Lemola (Professor)², Shyam Balasubramanian

(Consultant)³, Swaran Singh (Professor)⁴, Nicole KY Tang (Professor)¹^a

¹Department of Psychology, University of Warwick, Coventry, United Kingdom ²Department of Psychology, Bielefeld University, Bielefeld, Germany ³University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom

4Warwick Medical School, University of Warwick, Coventry, United Kingdom

*Joint first authorship (equal contributions)

^aCorresponding Author: Nicole KY Tang, Email: <u>n.tang@warwick.ac.uk</u>

ORCID IDs:

- J.L. Gillett: 0000-0002-7115-9938
- P. Karadag: 0000-0003-2655-7109
- K. Themelis: 0000-0002-0022-5272
- S. Lemola: 0000-0002-1314-6194
- S. Balasubramanian: 0000-0001-5149-3595
- N.K.Y. Tang: 0000-0001-7836-9965

ABSTRACT

Introduction: Previous qualitative and cross-sectional research has identified a strong sense of mental defeat in people with chronic pain who also experience the greatest levels of distress and disability. This study will adopt a longitudinal experience sampling design to examine the within-person link between the sense of mental defeat and distress and disability associated with chronic pain.

Methods and Analysis: We aim to recruit 198 participants (aged 18-65 years) with chronic pain, to complete two waves of experience sampling over 1 week, 6 months apart (Time 1 and Time 2). During each wave of experience sampling, the participants are asked to complete 3 short online surveys per day, to provide in-the-moment ratings of mental defeat, pain, physical and social activity, stress, mood, self-compassion, and attention using visual analogue scales (VAS). Sleep and physical activity will be measured using a daily diary as well as with wrist-actigraphy worn continuously by participants throughout each wave. Linear mixed models and Gaussian graphical models will be fit to the data to: (1) examine the within-person, day-to-day association of mental defeat with outcomes (i.e., pain, physical/social activity, medication use and sleep) (2) examine the dynamic temporal and contemporaneous networks of mental defeat with all outcomes and the hypothesised mechanisms of outcomes (i.e., perceived stress, mood, attention, and self-compassion).

STRENGTHS AND LIMITATIONS OF THE STUDY:

- This study provides the first longitudinal investigation of mental defeat in chronic pain to shed light on its temporal links with outcomes.
- A range of outcomes and hypothesised mechanisms will be assessed including pain, physical and social activity, medication use, sleep, stress, mood, attention, and self-compassion. Measures are repeated over a oneweek period, at two time-points each six-months apart.
- This study will use both self-reported and objective estimates of sleep and physical activity, via diaries and actigraphy longitudinally.
- The research is done remotely, at the participant's convenience and within their natural environment.
- Considerations must be given to effects of participants' COVID exposure on recruitment, subsequent attrition, and possible findings despite having had appropriate COVID screening and health and safety procedures in place.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

1. INTRODUCTION

Chronic pain is characterised as pain that persists or recurs beyond 3 months (1). It is highly prevalent, affecting around 30% of the population worldwide (2–4). Chronic pain conditions, namely low back pain and headaches, are consistently the top causes of years lived with disability (2,5) and reduced quality of life (6). People with chronic pain are three times as likely to have depression and anxiety disorders (7) and twice as likely to present a risk of suicide compared to the general population (8). Whilst some individuals manage to cope with the pain, others struggle to maintain daily activities. Understanding the factors that determine whether an individual can feel and function well- despite persistent pain- is crucial to advancing non-pharmacological management approaches for chronic pain, which have so far had a modest impact (9).

A concept proposed to help explain differences in the experience of painrelated distress and disability is mental defeat; a cognitive construct characterised by negative self-appraisals in relation to pain (10,11). The concept of defeat has its theoretical underpinnings in the study of post-traumatic stress disorder (PTSD) (12– 14) and depression (15,16), where it is respectively defined as the perceived loss of autonomy and a natural response to the loss of social status in a conflict situation. Empirical research has shown that a strong sense of mental defeat is associated with severe PTSD symptoms and poorer response to exposure treatment (12,14,17). The perception of defeat has also been shown to predict symptoms of depression independent of hopelessness (15), and has been implicated in psychological models of suicidal behaviour and suicidality (18–20).

Mental defeat in the context of chronic pain encapsulates people's psychological response to perceived threats of one's physical and psychological

Page 5 of 34

BMJ Open

autonomy. Daily experience of living with persistent and debilitating pain which does not respond to treatment is thought to be a repeated trigger of mental defeat, prompting negative appraisals of self in relation to pain (21). Consistently, qualitative explorations of patient experience have revealed patients reporting "defeat of the mind" and "the pain is taking over", with the pain seen as "an enemy" that "belittles [them] as a person" (11,22,23).

Using the Pain Self Perception Scale to measure mental defeat, it has been found that treatment-seeking patients with chronic pain have elevated levels of mental defeat compared to: patients with acute pain, patients with anxiety disorders, community volunteers with chronic pain, community volunteers with acute pain and pain-free volunteers (21). Mental defeat has also been found to be the predictor explaining the most variance in pain interference, depression, and psychological disability among chronic pain patients seeking specialist treatment, when compared to pain intensity, health anxiety, worry rumination, and pain catastrophising (11). It has moderate associations with sleep disturbances and functional disability (11) and negatively relates to pain self-efficacy even when anxiety, depression, pain catastrophising, and hopelessness are controlled for (24). Furthermore, mental defeat predicts suicide intent in patients with chronic pain above and beyond pain intensity (25). In pain-free volunteers, an activated sense of mental defeat appears to operate independently from existing pain-related psychological constructs such as pain catastrophising, in influencing mood and attentional disengagement from nociceptive stimuli (26). Together, these findings suggest how a person's selfperception in relation to pain matters in terms of predicting and explaining outcomes.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

However, most of the aforementioned studies of mental defeat in chronic pain are cross-sectional in design, and more direct evidence is required to establish the

BMJ Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

temporal and casual association implicated. This study adopts the experience sampling methodology (ESM) involving *in vivo* data gathering (using actigraphy, sleep diaries and daily online surveys) to examine the day-to-day association between mental defeat, symptoms, distress, and disability associated with chronic pain. Data will be collected over 7 days, allowing the study of any temporal withinperson relationships which may provide insight into clinically relevant questions such as whether mental defeat will be followed by higher pain, increased stress, greater attention to pain, increased medication usage, reduced physical and social activity and poorer sleep. The experience sampling exercise is repeated at 6 months to investigate how these indices may change over time and translate into distress and disability long-term. The primary objectives of this study are: (1) examine the withinperson, day-to-day association of mental defeat with outcomes (i.e., pain, physical/social activity, medication use and sleep), and (2) examine the dynamic temporal and contemporaneous networks of mental defeat with all outcomes and the hypothesised mechanisms of outcomes (i.e., perceived stress, mood, attention, and self-compassion).

Based on previous work (e.g. 11,21,25) we hypothesise that, for an individual, a strong sense of mental defeat will be associated with subsequent greater reports of pain, reduced physical and social activity, possible increased use of medication, and poorer sleep. Examinations of the dynamic temporal and contemporaneous networks of mental defeat with mechanisms and outcomes are novel and exploratory.

2. METHOD

2.1 Study Design

BMJ Open

As depicted in Figure 1, ESM are used to gather data prospectively over 1-week; at two-time points, each six months apart (T1 and T2). The length and frequency of assessment reflect our attempt to balance information needs with concerns of participation burden and possible attrition, participants are asked to continuously wear a medical-grade actigraphy device (MotionWatch 8©, manufactured by CamNTech Ltd) for 8 nights/7 days. They are asked to complete a sleep diary and respond to 3 short online surveys during the day. These surveys will provide in-the-moment measures of mental defeat, pain, medication use, physical activity and social activity, stress, mood, attention, and self-compassion using visual analogue scales (VAS).

Insert Figure 1 about here

2.2 Participants

Participants are adults aged 18-65 living with chronic non-cancer pain that has been

present or recurring for more than 3 months (27,28). Participant inclusion and

exclusion criteria are outlined in Table 1.

Table 1.

PARTICIPANT INCLUSION & EXCLUSION CRITERIA FOR PARTICIPATION Inclusion Criteria:

- > Aged between 18 65 (for focussing our study on working-age population).
- > Experience chronic non-cancer pain for at least 3 months.
- Stable treatment for duration of the study (6 months).
- English-speaking (for understanding and implementing the data collection procedure).
- Living in the UK (for postage of equipment).
- > Be able to provide informed consent.

Exclusion Criteria:

- Have any significant comorbid psychiatric (e.g., psychosis), medical (e.g., coronary heart diseases), neurological (e.g., Alzheimer's, Parkinson's, Epilepsy) or life-threatening conditions (e.g., cancer) that would impact pain experience, impede the ability to provide informed consent or complete the study.
- Have any other significant comorbid sleep disorder, e.g., sleep apnoea, restless leg syndrome, periodic limb movement disorder, narcolepsy or circadian rhythm disorders, which in the opinion of the research team would cofound the results of the study.
- Have elective surgery or procedures requiring general anaesthetic during the study.
- Have participated in another research study using an investigational product in the past 3-months.

We aim to recruit 198 participants to factor in an anticipated 20% attrition at T2. This will give 158 participants who complete the experience sampling procedure at both timepoints to generate up to 6636 temporally structured ratings for analysis (3 ratings x 7 days x 2 timepoints x 158 participants). There will be a maximum of 2528 observations of sleep data (8 nights of actigraphic data x 2 timepoints x 158 participants) and 7 days' of physical activity count data at 30-second epoch. This will give sufficient power to perform the planned analyses using Multilevel Mixed-Effects Models (29) and Graphical Gaussian Models (30).

2.3 Recruitment

Recruitment of participants started in April 2021 and is expected to end in May 2023. A variety of recruitment methods are being used, including social media, the NIHR Clinical Research Network, public engagement events, and peer-led support groups. We are also using online recruitment platforms to capture individuals with chronic pain with registered interest to take part in research. Finally, chronic pain patients at University Hospitals Coventry and Warwickshire are given information about the study during pain clinic appointments.

2.4 Measures

2.4.1 Screening Questionnaire

A brief online screening questionnaire is administered to assess eligibility. To provide the relevant information against the *a priori* inclusion and exclusion criteria, the screening questionnaire determines basic demographics (e.g., age, sex, ethnicity, employment status, education level) and health indicators (e.g., body mass index, average alcohol intake, smoking status). It also checks for pain characteristics, current treatment plans, e.g. plans for surgery in the next 6-months and current participation in clinical trials. Lastly, it considers comorbid health conditions, including the presence of any psychiatric, medical, neurological or sleep disorders.

2.4.2 Baseline Questionnaire

Eligible participants are asked to complete a baseline questionnaire which includes validated measures of variables related to mental defeat, pain, physical and social activity, sleep, psychological states and quality of life (see Table 2 for full list). Data from these questionnaires are not used in the planned analyses of the current study except for characterising the sample at baseline.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Table 2.			
QUESTIONNAIRE MEASURES INCL	UDED		
Measure	Scale Used		
Key Variable of Interest			
Mental defeat	Pain Self-Perception Scale (PSPS)(21)		
Pain-Related Measures			
Pain intensity & interference	Brief Pain Inventory-Short Form (BPI- sf)(31)		
Pain vigilance and awareness	Pain Vigilance & Awareness Questionnaire (PVAQ)(32)		
Pain-related fear of movement	Tampa Scale of Kinesiophobia (TSK- 11)(33)		

Patterns of activity (pain-specific)	Patterns of Activity Measure for Pain (POAM-P)(34)
Pain catastrophising	Pain Catastrophizing Scale (PCS)(35)
Pain self-efficacy	Pain Self-Efficacy Questionnaire (PSEQ)(36)
Physical & Social Activity Measures	
Physical activity	International Physical Activity Questionnaire (IPAQ)(37)
Social activity	Social Activity Log (SAL)(38)
Sleep-Related Measure	
Insomnia symptom severity	Insomnia Severity Index (ISI)(39)
Psychological States	
Stress	Perceived Stress Scale (PSS)(40)
Anxiety & depression	Hospital Anxiety & Depression Scale (HADS)(41)
Suicidal behaviour	Suicidal Behaviour Questionnaire Revised (SBQ-R)(42)
Self-compassion	Self-Compassion Scale Short Form (SCS-sf)(43)
Quality of Life Measure	
General health and quality of life	EQ-5D-5L(44)

2.4.3 Sleep Diary

 The morning section of the Consensus Sleep Diary (45) is administered daily throughout the tracking period to collect self-reported information on sleep. The sleep diary asks participants what time they went to bed, what time they attempted to go to sleep, how long it took them to fall asleep (sleep onset latency), how many times did they wake up from sleep (not including final awakening), final wake up time, what time did they get out of bed, total sleep duration (hours and minutes), perceived sleep-quality and how rested or refreshed they felt after waking. Participants can also provide additional information that they feel is relevant to their sleep. We added two extra questions to the sleep diary to obtain in-the-moment ratings of pain and mood upon waking. These possible covariates are assessed via

BMJ Open

two VAS both ranging from 0-10, whereby for pain 0= *no pain at all* and 10= *worst pain imaginable* and for mood 0= *very bad* and 10= *very good*.

2.4.4 Daily Survey

The daily survey allows participants to provide ratings of mental defeat, pain, medication use, physical and social activity, stress, mood, attention, and selfcompassion (see Figure 1 for a schedule of administration). We use adapted or shortened versions of original scales to decrease participant burden. The surveys are short (<5 minutes completion time) and are equally spaced 2.5 hours apart to capture experiences at different time points throughout the day. The surveys are sent out following a choice of pre-determined schedules to match participants' typical sleep-wake patterns. The earliest schedule starts with a sleep diary at 06:30 and the first daily survey commences at 09:00, whereas the latest schedule starts with a sleep diary at 13:30 and the first daily survey commences at 16:00. The timing of these measures avoids unsociable hours, as no prompts arrive between the hours of 23:00 and 06:00 inclusive.

We use Survey Signal to send out auto-prompts at specified times via SMS to participants' smartphones. This enables accessibility for participants to complete surveys in a timely fashion, while remaining convenient, and does not require an app download or adjusted personal mobile settings. The surveys are administered, recorded, and returned via Qualtrics and are time-stamped at the time of commencement and completion. The daily surveys comprise multiple VAS with varying left to right anchors, as shown in Table 3.

Table 3.				
DAILY SURV	EY RATING SCALES			
Construct	Item (measure)	Scale	Anchors	

Mental defeat	Since waking up today, how much has the pain brought back to life memories of times when you felt the pain had taken over?	0 – 10	0= not at all to 10= very much so
Pain intensity	What is your current pain level?	0 – 10	0 = no pain to 10 = worst pain imaginable
Pain interference	 Since waking up today, how much has your pain impacted on a) Your daily routine (including work)? b) Your relationship(s)? c) How you think or feel about the future? d) How you think or feel about yourself? 	0 – 10	0= not much impact/interference to 10 = a great deal of impact/interference
Medication use	Since waking up today, would you say that you have taken more or less medication than usual?	-5 – 5	-5= a lot less than usual, 0 = no difference, 5 = a lot more than usual
Physical activity	Since waking up today, how physically active has you been?	0 – 10	0= not physically active at all to 10= very physically active
Social activity	Since waking up today, how socially engaged have you been?	0 – 10	0= not socially engaged at all to 10= very socially engaged
Stress	What is your current stress level?	0 – 10	0= no stress at all to 10= highest level of stress possible
Mood	What is your current mood?	0 – 10	0= very bad to 10 = very good
Attention to pain	Since waking up today, how much of the time have you been thinking about your pain?	0 – 10	0= none of the time to 10= a great deal of the time
Focus of attention	Since waking up today, has the focus of your attention been a) Inward or outward	0 – 10	0 = inward to 10 outward 0 = body to 10= mind

	b) On the body or mind		
Self- compassion	Since waking up today, how kinda) to yourself have you been?b) to others have you been?	0 – 10	0= not at all to 10= very much so

Note. VAS questions with corresponding anchors that are presented in Survey 1 are summarised above. These questions appear identically in Surveys 2 and 3, except instead of starting questions with "since waking up today..." in Surveys 2 and 3 each question begins "in the last 2.5 hours...".

2.4.5 Actigraphy

Actigraphs are light, compact accelerometer-based devices that have been used to generate objective estimates of sleep parameters for several decades (46). Actigraphy has been well-evidenced as a suitable methodology for non-intrusive athome sleep assessment (47–49). Although polysomnography continues to be considered the gold standard for sleep recording, wrist-actigraphy has the advantage of offering cost-effective continuous recording in participants' home environment (50). Thus providing more ecologically valid information compared to polysomnography (50).

For the present study, MotionWatch 8© actigraphs are worn by participants on their non-dominant wrist during the study. The MotionWatch is a medical-grade triaxial actigraphy device containing a piezoelectric accelerometer to record duration, integration, and number of movements in all directions. This data enables the research team to chart sleep and physical activity across the experience sampling periods that are then downloaded for analysis using MotionWare© software (Cambridge Neurotechnology Ltd., Cambridge, UK) with validated algorithms. The key sleep parameters we are interested in are sleep efficiency (SE) and total sleep time (TST). The key physical activity parameter is total activity counts tabulated by week, day, and/or hour.

2.5 Procedure

To participate, individuals respond to a study advert via phone, email or by following a direct link to the information leaflet. Interested participants are required to complete the screening questionnaire and contact information form, following which a member of the research team determines eligibility to the study by checking against the inclusion/exclusion criteria. Individuals who meet the inclusion criteria are informed of their eligibility via email and invited to participate. Individuals who do not meet the inclusion criteria are informed via email that they are not eligible, thanked and debriefed.

Eligible participants that agree to participate are sent a link to an online consent form to complete via Qualtrics. Once informed consent has been obtained, participants have a phone call with a member of the research team to arrange their participation and highlight some key training points for the study. All participants receive the study materials (an invitation letter, a cleaned and packaged MotionWatch for borrowed use, two individually wrapped disinfectant wipes, an addressed, pre-paid return envelope, and an information booklet) via UK postal delivery. To accompany the information booklet, participants are emailed a link to an instructional video (see supplementary file 1) demonstrating how to use the MotionWatch devices appropriately and reiterating the schedule of measurement/engagement required during participation. Participants are instructed to wear the MotionWatch continuously for the 7-day experience sampling period and are required to press an event marker on the device when they plan to go to sleep and when they get out of bed, following their main sleep period. Participants are also asked to answer the sleep diary and three short surveys each day.

Page 15 of 34

BMJ Open

The timing of the daily surveys/sleep diary are individually anchored by participants' typical sleep-wake patterns, to accommodate and control for variations in individuals' circadian rhythms. For example, if a participant indicates that they usually wake at 08:00, a typical day during the experience sampling period on this schedule would be as follows: upon getting out of bed, the participant presses the event marker on the MotionWatch and will receive the first text message (with a link to the sleep diary) at 08:30 – allowing them to report their sleep experiences as soon as practical after waking. Throughout the day, the participant will receive three further text message prompts, each containing a link to the short online survey. Survey 1 (S1) is received at 11:00, survey 2 (S2) at 13:30 and survey 3 (S3) at 15:00. The links to each survey remains open for 2.5 hours, before expiring at the time the following survey is triggered. Finally, the participant will be required to press the event marker at "lights out" or when beginning trying to sleep. This process is identical for each day in the experience sampling period. After the final awakening on the last day, the participant removes the MotionWatch, and packages it in the box ready for return-postage to the Lab. The MotionWatch data is processed on-site at the Lab, before being formatted into a personalised breakdown for the participant, which is emailed to them along with a gift voucher within two weeks of receipt of the returned equipment. This procedure is repeated in its entirety for the follow-up T2 assessment. The debrief is administered upon study completion.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2.6 Participant Reimbursement

To thank the participants for their time and participation, they are given a £10 gift voucher for each timepoint they complete. Additionally, participants are provided with

BMJ Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

a personalised breakdown of their actigraphy data created by the research team. No evaluative feedback on sleep quality and physical activity patterns is given.

2.7 Adverse Event Recording and Management

This is a low-risk observational study, and no major adverse events are anticipated. We offer health and safety training at the outset, instructing participants not to respond to survey text messages if it is not safe to do so, e.g., when driving, operating machinery, or crossing the road. Before participation commences, participants are instructed to report any adverse events that occur during the assessment periods to the research team.

Adverse events that are related to the study and/or unrelated adverse events are recorded and reported to the study sponsor according to reporting requirements. Unrelated and expected adverse events may include but are not limited to illness, hospitalisation or day-surgery that occurs during the assessment period. An adverse event that a small number of participants may experience is discomfort or irritation caused by wearing the MotionWatch. Before participants begin the study, we advise them to inform the researcher if they experience any skin irritation. If the irritation is very mild and they wish to continue, we recommend placing a small piece of tissue underneath the watch or to place the silicon strap on top of their sleeve to avoid direct skin contact. In the unlikely event of an unexpected adverse event that is deemed to be severe and related to the study, the research team would immediately pause the study and send an expedited report to the study sponsor. Events will be followed up until they are resolved or when a final outcome has been reached.

2.8 Patient and Public Involvement

This protocol has been developed in partnership with two patient representatives with lived experience of chronic pain. One representative (PR) provided feedback on participant-facing materials and piloted the MotionWatch for at-home use. DD participated in study-related procedures and also commented on the manuscript for readability.

2.9 COVID Related Considerations

To enable the study to take place during the COVID-19 pandemic, while adhering to governmental and institutional COVID-19 guidance, the operational aspects of the protocol have been adapted for remote participation. The MotionWatch devices are all sanitised, prepared and packaged for participation in a lab environment. A short COVID checklist has been implemented before each wave of tracking (see e'ie supplementary file 2).

3. DATA MANAGEMENT PLAN

The study data collected from the questionnaire, sleep diary and daily surveys will be stored securely on Qualtrics and subsequently downloaded as password protected databases to undergo data quality checks and pseudo-anonymisation by the research team. Access to these databases will be restricted to approved members of the research team. Once data completeness and quality are verified, electronic data on Qualtrics will be deleted.

Actigraphic data collected using MotionWatch 8[©] are downloaded using Motionware© software upon each watch's return to the lab. The downloaded data are saved via their assigned ID number and will be held securely and separately from the study data.

The Chief Investigator (NT) of the project will act as the data controller. All data generated by the research programme will be analysed by the research team either on site at the University of Warwick or in a private workspace in the event of remote-working, as per the University's Off-Campus Working Policy. In line with the University's Research Code of Conduct, data will be retained in electronic format for at least 10 years from the date of any publication that is based upon it.

4. STATISTICAL METHODS

All participants who meet eligibility criteria will be included in analyses; including those who wish to withdraw from the study but consent to having any data already collected analysed. Those who withdraw and do not consent to the data being analysed will be excluded from analyses.

Descriptive statistics will be used to characterise the sample based on information from the screening and baseline questionnaires. Means and standard deviations/95% confidence intervals will be reported for continuous variables, whereas frequencies and percentages will be used for reporting categorical variables.

To evaluate the within-person temporal relationship between mental defeat (predictor) and pain, physical and social activity, medication use and sleep (outcomes), we will pool the daily survey ratings from all participants across waves of assessment. Linear mixed models with a time-lagged design will be fit to the data. We will fit one model for each outcome. For each analysis, we will first estimate a maximal random effects model with all random slopes and random intercepts (for 'time of day [survey 1, 2, 3]', 'day [1, 2, 3, 4, 5, 6, 7]' and 'wave [1, 2]') and successively simplify the random effect structure until the model converges. Nested

Page 19 of 34

BMJ Open

comparisons will be made between the final models with the intercepts-only models. The significance of each model will be assessed using a likelihood ratio test (LRT). P-values will be adjusted using false discovery rate to account for alpha error accumulation (FDR; (51)). The best fitting model will be determined using Aikaike Information Criteria (AIC) (52,53) and Bayesian Information Criteria (BIC) (54), where lower values of the AIC and BIC indicate a better fit. As secondary analyses, we will repeat the above analyses with the hypothesised mechanisms of outcomes (stress, mood, attention, self-compassion) as the dependent variables. Both the statistical software SPSS (IBM Corp., Armonk, NY, USA) and the "Ime4" package (55) for R (56) will be used.

To explore the within-individual temporal and contemporaneous relationships as well as between-individual relationships between mental defeat and the outcomes and hypothesised mechanisms of interest, we will use Gaussian graphical models (GGM; (30)). To obtain sufficient power for the GGMs, it is recommended to have more than 20 measurements and at least 20 pairs of comparisons (57). The design of the current study will yield 21 measurements per participant per wave. That will give 20 pairs of comparisons for modelling changes across days, 14 pairs of comparisons for modelling changes within day, and 7 pairs of comparisons for modelling changes at different times of the day. We will therefore not seek to model changes at different times of the day, but to focus on modelling changes across and within day by pooling together data from both waves of assessment. Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

We will use the mIVAR (Version 0.3.2) package (57,58), or similarly suitable but more up-to-date packages, for R (56) to analyse the multivariate time series data. We will report three kinds of network; temporal (to indicate whether a variable predicts another variable (or itself) at the next measurement point, controlling for all other variables in the network at the previous measurement point), contemporaneous (to indicate the within-person relationships between variables, having adjusted for the effect of all variables in the network and the temporal effects) and between-person (to indicate relationships between person-means of variables, partialling out the effect of all other variables in the network).

Additional secondary analyses will be performed for research questions other than the 2 main ones stated here. Any deviation(s) from the original statistical plan will be described and justified in our subsequent reportings.

5. ETHICS & DISSEMINATION

 This research forms part of the wider MRC-funded Warwick Study of Mental Defeat in Chronic Pain ("WITHIN" Study). The current protocol has been approved by the Health Research Authority and West Midlands – Solihull Research Ethics Committee (Reference Number: 17/WM0053, p, IRAS project ID: 223190). The University of Warwick (Research Impact Services, University of Warwick, Coventry, CV4 7AL) acts as the Sponsor for the study. The study is being conducted in adherence with the Declaration of Helsinki, Warwick Standard Operating Procedures and applicable UK legislation. Results from this study will be written as reports, to be disseminated in peer-reviewed journals, at conferences and patient and public engagement events.

6. AUTHOR'S CONTRIBUTIONS AND ACKNOWLEDGEMENTS

6.1 Authors' Contributions

NT conceived the research idea and developed the theory and plan for this study. JG and PK are joint first author as they contributed equally to all aspects of the study

BMJ Open

and are responsible for implementing the protocol, creating study materials, data acquisition and management and drafting the original manuscript. KT and NT are responsible for critical revisions of the manuscript. All authors (JG, PK, KT, Y-ML, SL, SB, SS, NT) contributed to the study development and reviewed, commented, and approved the manuscript.

6.2 Acknowledgements

The authors would like to thank all the participants who are involved in the study and the UK chronic pain charities who have shared our study on relevant webpages and social media platforms. We would also like to thank our PPI representatives (PR & DD) for their input into the study design and feasibility, including Debra Dulake (DD) who also commented on the manuscript. Finally, we would like to thank Michelle Pun, Emily Ashton and Chloe Osei-Cobbana who have supported the data collection process under the Psychology Research Skills Development Scheme (PRSDS) at the University of Warwick. Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

7. COMPETING INTERESTS

The authors have no competing interests.

8. FUNDING

This protocol is part of a wider study (Warwick Study of Mental Defeat in Chronic Pain that is supported by Medical Research Council (MRC) grant number: MR/S026185/1 to NKYT. For the purpose of open access, the corresponding author has applied a Creative Commons Attribution (CC BY) licence (where permitted by UKRI, 'Open Government Licence' or 'Creative Commons Attribution No-derivatives

(CC BY-ND) licence' may be stated instead) to any Author Accepted Manuscript version arising from this submission. JLG was funded by the University of Warwick Departmental PhD Fellowship, under the supervision of NKYT. The funders have no role in study design, data collection and analysis, decision to publish or preparation of this manuscript.

9. DATA SHARING STATEMENT

Once available, cleaned, anonymised data generated from this study will be made available on open-access repository.

10. REFERENCES

 Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. Chronic pain as a symptom or a disease: The IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11) [Internet]. Vol. 160, Pain. Lippincott Williams and Wilkins; 2019 [cited 2022 Jun 14]. p. 19–27. Available from:

https://journals.lww.com/pain/Fulltext/2019/01000/Chronic_pain_as_a_sympto m_or_a_disease__the_IASP.3.aspx

- James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789–858.
- Dahlhamer J, Lucas J, Zelaya, C, Nahin R, Mackey S, DeBar L, et al.
 Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults —

BMJ Open

	United States, 2016. Morb Mortal Wkly Rep [Internet]. 2018 Sep 9 [cited 2022
	Jun 14];67(36):1001–6. Available from: /pmc/articles/PMC6146950/
4.	Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best
	practices, and new advances [Internet]. Vol. 397, The Lancet. Elsevier; 2021
	[cited 2022 Jun 14]. p. 2082–97. Available from:
	http://www.thelancet.com/article/S0140673621003937/fulltext
5.	Vos T, Abajobir AA, Abbafati C, Abbas KM, Abate KH, Abd-Allah F, et al.
	Global, regional, and national incidence, prevalence, and years lived with
	disability for 328 diseases and injuries for 195 countries, 1990-2016: A
	systematic analysis for the Global Burden of Disease Study 2016. Lancet
	[Internet]. 2017 Sep 16 [cited 2022 Jun 29];390(10100):1211–59. Available
	from: https://research.polyu.edu.hk/en/publications/global-regional-and-
	national-incidence-prevalence-and-years-lived
6.	Fernández A, Saameño JÁB, Pinto-Meza A, Luciano JV, Autonell J, Palao D,
	et al. Burden of chronic physical conditions and mental disorders in primary
	care. Br J Psychiatry [Internet]. 2010 Apr [cited 2022 Jun 14];196(4):302–9.
	Available from: https://www.cambridge.org/core/journals/the-british-journal-of-
	psychiatry/article/burden-of-chronic-physical-conditions-and-mental-disorders-
	in-primary-care/1F431966FA03440CA86EE7B2B2028FB6
7.	Von Korff M, Crane P, Lane M, Miglioretti DL, Simon G, Saunders K, et al.
	Chronic spinal pain and physical-mental comorbidity in the United States:
	Results from the national comorbidity survey replication. Pain [Internet]. 2005
	Feb [cited 2022 Jun 28];113(3):331–9. Available from:
	https://journals.lww.com/pain/Fulltext/2005/02000/Chronic_spinal_pain_and_p
	hysical_mental.13.aspx

8. Tang NKY, Crane C. Suicidality in chronic pain: A review of the prevalence, risk factors and psychological links [Internet]. Vol. 36, Psychological Medicine. Cambridge University Press; 2006 [cited 2022 Jun 14]. p. 575–86. Available from: https://www.cambridge.org/core/journals/psychologicalmedicine/article/abs/suicidality-in-chronic-pain-a-review-of-the-prevalence-riskfactors-and-psychological-links/D3093AA52A611348B8F90CF0972380C5

 Williams AC d. C, Fisher E, Hearn L, Eccleston C. Psychological therapies for the management of chronic pain (excluding headache) in adults [Internet]. Vol. 2020, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2020 [cited 2022 Jun 14]. Available from:

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007407.pub4/ full

- Tang NKY, Salkovskis PM, Hanna M. Mental Defeat in Chronic Pain: Initial Exploration of the Concept. Clin J Pain [Internet]. 2007 Mar [cited 2020 Apr 16];23(3):222–32. Available from: http://journals.lww.com/00002508-200703000-00005
- Tang NKY, Goodchild CE, Hester J, Salkovskis PM. Mental defeat is linked to interference, distress and disability in chronic pain. Pain. 2010 Jun 1;149(3):547–54.
- Ehlers A, Maercker A, Boos A. Posttraumatic stress disorder following political imprisonment: The role of mental defeat, alienation, and perceived permanent change. J Abnorm Psychol [Internet]. 2000 [cited 2022 Jun 28];109(1):45–55. Available from: /record/2000-13847-006
- 13. Dunmore E, Clark DM, Ehlers A. A prospective investigation of the role of cognitive factors in persistent Posttraumatic Stress Disorder ({PTSD}) after

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2		
2 3 4		physical or sexual assault. Behav Res Ther. 2001 Sep;39(9):1063–84.
5 6	14.	Dunmore E, Clark DM, Ehlers A. Cognitive factors involved in the onset and
7 8		maintenance of posttraumatic stress disorder (PTSD) after physical or sexual
9 10 11		assault. Behav Res Ther. 1999 Sep 1;37(9):809–29.
12 13	15.	Gilbert P, Allan S. The role of defeat and entrapment (arrested flight) in
14 15		depression: An exploration of an evolutionary view. Psychol Med [Internet].
16 17		1998 [cited 2022 Jun 14];28(3):585–98. Available from:
18 19 20		https://www.cambridge.org/core/journals/psychological-
20 21 22		medicine/article/abs/role-of-defeat-and-entrapment-arrested-flight-in-
23 24		depression-an-exploration-of-an-evolutionary-
25 26 27		view/A28C75514B33418F797269B1C276AC87
27 28 29	16.	Price J, Sloman L, Gardner R, Gilbert P, Rohde P. The social competition
30 31		hypothesis of depression [Internet]. Vol. 164, British Journal of Psychiatry.
32 33		Cambridge University Press; 1994 [cited 2022 Jun 14]. p. 309–15. Available
34 35 36		from: https://www.cambridge.org/core/journals/the-british-journal-of-
37 38		psychiatry/article/abs/social-competition-hypothesis-of-
39 40		depression/18622D076771AB200A26D318AF52A1D9
41 42 42	17.	Ehlers A, Clark DM, Dunmore E, Jaycox L, Meadows E, Foa EB. Predicting
43 44 45		response to exposure treatment in PTSD: The role of mental defeat and
46 47		alienation. J Trauma Stress [Internet]. 1998 Jul 1 [cited 2022 Jun
48 49		28];11(3):457–71. Available from:
50 51 52		https://onlinelibrary.wiley.com/doi/full/10.1023/A%3A1024448511504
53 54	18.	Williams M. Cry of Pain: Understanding Suicide and the Suicidal Mind
55 56		[Internet]. 2014 [cited 2022 Jun 14]. 304 p. Available from:
57 58		https://books.google.co.uk/books?hl=en&lr=&id=msamAaAAQBAJ&oi=fnd&pa
59 60		

2	
ر ۸	
4	
5	
6	
7	
8	
9	
10	
11	
12	
12	
11	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
25	
20	
27	
28	
29	
30	
31	
32	
33	
34	
35	
26	
20	
3/	
38	
39	
40	
41	
42	
43	
44	
45	
75	
40	
4/	
48	
49	
50	
51	
52	
53	
54	
55	
22	
20	
5/	
58	
59	
60	

1

=PT6&dq=+Williams,+M.+(2014).+Cry+of+pain:+understanding+suicide+and+t he+suicidal+mind.+Hachette+UK.&ots=ssXWHmmFa7&sig=k3HIS7rgmKO0C XiZiu5yLb4FkBA&redir_esc=y#v=onepage&q=Williams%2C M.

- O'Connor RC, Kirtley OJ. The integrated motivational-volitional model of suicidal behaviour [Internet]. Vol. 373, Philosophical Transactions of the Royal Society B: Biological Sciences. The Royal Society; 2018 [cited 2022 Jun 14]. Available from: https://royalsocietypublishing.org/doi/10.1098/rstb.2017.0268
- 20. Johnson J, Gooding PA, Wood AM, Tarrier N. Resilience as positive coping appraisals: Testing the schematic appraisals model of suicide (SAMS). Behav Res Ther [Internet]. 2010 Mar 1 [cited 2020 Mar 25];48(3):179–86. Available from:

https://reader.elsevier.com/reader/sd/pii/S0005796709002484?token=047BFC 4DC2AA4BAC774ED9741F8C3365F5796A2CDB6555ABD4E520173D20517 0BFF3942B9E193578519667E13A37C052&originRegion=eu-west-1&originCreation=20211006105621

Tang NKY, Salkovskis PM, Hanna M. Mental defeat in chronic pain: Initial exploration of the concept. Clin J Pain [Internet]. 2007 Mar [cited 2022 Jun 14];23(3):222–32. Available from:

https://journals.lww.com/clinicalpain/Fulltext/2007/03000/Mental_Defeat_in_Ch ronic_Pain__Initial_Exploration.5.aspx

22. Smith JA, Osborn M. Pain as an assault on the self: An interpretative phenomenological analysis of the psychological impact of chronic benign low back pain. Psychol Heal [Internet]. 2007 Jul [cited 2022 Jun 14];22(5):517–34. Available from:

https://www.tandfonline.com/doi/abs/10.1080/14768320600941756

Page 27 of 34

2		
2 3 4	23.	Tang NKY, Salkovskis PM, Hodges A, Soong E, Hanna MH, Hester J. Chronic
5 6		pain syndrome associated with health anxiety: A qualitative thematic
7 8 0		comparison between pain patients with high and low health anxiety. Br J Clin
9 10 11		Psychol [Internet]. 2009 Mar 1 [cited 2022 Jun 14];48(1):1–20. Available from:
12 13		https://onlinelibrary.wiley.com/doi/full/10.1348/014466508X336167
14 15	24.	Hazeldine-Baker CE, Salkovskis PM, Osborn M, Gauntlett-Gilbert J.
16 17 19		Understanding the link between feelings of mental defeat, self-efficacy and the
19 20		experience of chronic pain. Br J Pain [Internet]. 2018 May 16 [cited 2022 Jun
21 22		14];12(2):87–94. Available from:
23 24 25		http://www.ncbi.nlm.nih.gov/pubmed/29796260
25 26 27	25.	Tang NKY, Beckwith P, Ashworth P. Mental defeat is associated with suicide
28 29		intent in patients with chronic pain. Clin J Pain. 2016;32(5):411–9.
30 31	26.	Collard VEJ, Gillett JL, Themelis K, Tang NKY. An exploratory investigation
32 33 34		into the effects of mental defeat on pain threshold, pain rating, pain
35 36		anticipation, and mood. Curr Psychol [Internet]. 2021 Mar 10 [cited 2022 Jun
37 38		14];1–12. Available from: https://link.springer.com/article/10.1007/s12144-021-
39 40 41		01548-3
42 43	27.	Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised
44 45		International Association for the Study of Pain definition of pain: concepts,
46 47		challenges, and compromises [Internet]. Vol. 161, Pain. NIH Public Access;
48 49 50		2020 [cited 2022 Jun 14]. p. 1976–82. Available from:
51 52		/pmc/articles/PMC7680716/
53 54	28.	NICE. Chronic pain (primary and secondary) in over 16s: assessment of all
55 56 57		chronic pain and management of chronic primary pain [Internet]. NICE
58 59		Guidelines. 2021 [cited 2022 Jun 14]. NICE guideline [NG193]. Available from:
60		

BMJ Open

2		
3 4		https://www.ncbi.nlm.nih.gov/books/NBK569983/bin/niceng193er6_bm1.pdf
5 6	29.	Magezi D a. Linear mixed-effects models for within-participant psychology
7 8		experiments: an introductory tutorial and free, graphical user interface
9 10 11		(LMMgui). Front Psychol [Internet]. 2015;6(January):1–7. Available from:
12 13		http://journal.frontiersin.org/Journal/10.3389/fpsyg.2015.00002/abstract
14 15	30.	Epskamp S, Borsboom D, Fried EI. Estimating psychological networks and
16 17		their accuracy: A tutorial paper. Behav Res Methods [Internet]. 2018 Feb 1
18 19 20		[cited 2022 Jun 14];50(1):195–212. Available from:
21 22		https://link.springer.com/article/10.3758/s13428-017-0862-1
23 24	31.	Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain
25 26 27		Inventory. [Internet]. Vol. 23, Annals of the Academy of Medicine, Singapore.
28 29		1994 [cited 2022 Jun 14]. p. 129–38. Available from:
30 31		https://europepmc.org/article/med/8080219
32 33	32.	Roelofs J, Peters ML, McCracken L, Vlaeyen JWS. The pain vigilance and
35 36		awareness questionnaire (PVAQ): Further psychometric evaluation in
37 38		fibromyalgia and other chronic pain syndromes. Pain. 2003 Feb 1;101(3):299-
39 40		306.
41 42 43	33.	Woby SR, Roach NK, Urmston M, Watson PJ. Psychometric properties of the
43 44 45		TSK-11: A shortened version of the Tampa Scale for Kinesiophobia. Pain.
46 47		2005 Sep 1;117(1–2):137–44.
48 49	34.	Cane D, Nielson WR, McCarthy M, Mazmanian D. Pain-related activity
50 51 52		patterns: Measurement, interrelationships, and associations with psychosocial
52 53 54		functioning. Clin J Pain [Internet]. 2013 May [cited 2022 Jun 14];29(5):435–42.
55 56		Available from:
57 58		https://iournals.lww.com/clinicalpain/Fulltext/2013/05000/Pain_related_Activity
59 60		

1

Page 29 of 34

BMJ Open

1 ว		
2 3 4		_PatternsMeasurement,.8.aspx
5 6	35.	Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale:
7 8 0		Development and Validation. Psychol Assess. 1995;7(4):524–32.
9 10 11	36.	Nicholas MK. The pain self-efficacy questionnaire: Taking pain into account.
12 13		Eur J Pain. 2007 Feb 1;11(2):153–63.
14 15	37.	Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et
16 17 18		al. International physical activity questionnaire: 12-Country reliability and
19 20		validity. Med Sci Sports Exerc [Internet]. 2003 [cited 2022 Jun 14];35(8):1381-
21 22		95. Available from: http://www.acsm-msse.org
23 24 25	38.	Syrjala KL, Stover AC, Yi JC, Artherholt SB, Abrams JR. Measuring social
26 27		activities and social function in long-term cancer survivors who received
28 29		hematopoietic stem cell transplantation. Psychooncology [Internet]. 2010 May
30 31 32		1 [cited 2022 Jun 27];19(5):462–71. Available from:
33 34		https://onlinelibrary.wiley.com/doi/full/10.1002/pon.1572
35 36	39.	Bastien CH, Vallières A, Morin CM. Validation of the insomnia severity index
37 38		as an outcome measure for insomnia research. Sleep Med. 2001 Jul
39 40 41		1;2(4):297–307.
42 43	40.	Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J
44 45 46 47 48 49 50 51 52 53 54 55 56 57		Health Soc Behav. 1983;24(4):385–96.
	41.	Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta
		Psychiatr Scand [Internet]. 1983 Jun 1 [cited 2018 Apr 28];67(6):361–70.
		Available from: http://doi.wiley.com/10.1111/j.1600-0447.1983.tb09716.x
	42.	Osman A, Bagge CL, Gutierrez PM, Konick LC, Kopper BA, Barrios FX. The
		suicidal behaviors questionnaire-revised (SBQ-R): Validation with clinical and
58 59 60		nonclinical samples. Assessment [Internet]. 2001 Jul 26 [cited 2022 Jun

2	
2	
4	
ر م	
0 7	
/	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
20	
29	
30 31	
27	
∠2 בב	
<u>د</u> د	
34 25	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
00	

1

14];8(4):443–54. Available from:

https://journals.sagepub.com/doi/abs/10.1177/107319110100800409

- Raes F, Pommier E, Neff KD, Van Gucht D. Construction and factorial validation of a short form of the Self-Compassion Scale. Clin Psychol Psychother [Internet]. 2011 May 1 [cited 2022 Jun 14];18(3):250–5. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/cpp.702
- Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al.
 Development and preliminary testing of the new five-level version of EQ-5D
 (EQ-5D-5L). Qual Life Res [Internet]. 2011 Dec 9 [cited 2022 Jun
 14];20(10):1727–36. Available from:

https://link.springer.com/article/10.1007/s11136-011-9903-x

45. Carney CE, Buysse DJ, Ancoli-Israel S, Edinger JD, Krystal AD, Lichstein KL, et al. The consensus sleep diary: Standardizing prospective sleep self-monitoring [Internet]. Vol. 35, Sleep. Oxford Academic; 2012 [cited 2022 Jun 14]. p. 287–302. Available from:

https://academic.oup.com/sleep/article/35/2/287/2558899

- 46. Ancoli-Israel S. Actigraphy. Princ Pract Sleep Med. 2005;1459–67.
- 47. Williams JM, Taylor DJ, Slavish DC, Gardner CE, Zimmerman MR, Patel K, et al. Validity of Actigraphy in Young Adults With Insomnia. https://doi.org/101080/1540200220181545653 [Internet]. 2018 Jan 2 [cited 2022 Jun 27];18(1):91–106. Available from:

https://www.tandfonline.com/doi/abs/10.1080/15402002.2018.1545653

- 48. Mccall C, Mccall WV. Comparison of actigraphy with polysomnography and sleep logs in depressed insomniacs. J Sleep Res. 2012 Feb;21(1):122–7.
- 49. Fekedulegn D, Andrew ME, Shi M, Violanti JM, Knox S, Innes KE. Actigraphy-

BMJ Open

2		
3 4		Based Assessment of Sleep Parameters. Ann Work Expo Heal [Internet]. 2020
5 6		Apr 30 [cited 2022 Jun 27];64(4):350–67. Available from:
7 8		https://academic.oup.com/annweh/article/64/4/350/5735350
9 10 11	50.	Ancoli-Israel S, Martin JL, Blackwell T, Buenaver L, Liu L, Meltzer LJ, et al.
12 13		The SBSM Guide to Actigraphy Monitoring: Clinical and Research
14 15		Applications. https://doi.org/101080/1540200220151046356 [Internet]. 2015
16 17		Jul 17 [cited 2022 Jun 27];13:S4–38. Available from:
18 19 20		https://www.tandfonline.com/doi/abs/10.1080/15402002.2015.1046356
21 22	51.	Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical
23 24 25		and Powerful Approach to Multiple Testing. J R Stat Soc Ser B [Internet]. 1995
26 27		Jan 1 [cited 2022 Jun 28];57(1):289–300. Available from:
28 29		https://onlinelibrary.wiley.com/doi/full/10.1111/j.2517-6161.1995.tb02031.x
30 31	52.	Akaike H. Information Theory and an Extension of the Maximum Likelihood
32 33 34		Principle. In Springer, New York, NY; 1998 [cited 2022 Jun 27]. p. 199–213.
35 36		Available from: https://link.springer.com/chapter/10.1007/978-1-4612-1694-
37 38		0_15
39 40	53.	Akaike H. A New Look at the Statistical Model Identification. IEEE Trans
41 42 43		Automat Contr. 1974;19(6):716–23.
44 45	54.	Schwarz SG. "Estimating the Dimension of a Model." Ann Stat [Internet]. 1978
46 47		[cited 2022 Jun 27];6(2):461–4. Available from:
48 49 50		http://www.citeulike.org/user/abhishekseth/article/90008
51 52	55.	Bates D, Mächler M, Bolker BM, Walker SC. Fitting linear mixed-effects
53 54		models using Ime4. J Stat Softw [Internet]. 2015 Jun 23 [cited 2022 Jun
55 56		27];67(1). Available from: https://arxiv.org/abs/1406.5823v1
58 59 60	56.	R Core Team. R: A Language and Environment for Statistical Computing.

Vienna R foundation for Statistical Computing.; 2012.

57. Epskamp S, Waldorp LJ, Mõttus R, Borsboom D. The Gaussian Graphical

Model in Cross-Sectional and Time-Series Data. Multivariate Behav Res

[Internet]. 2018 Jul 4 [cited 2022 Jun 29];53(4):453-80. Available from:

https://www.tandfonline.com/doi/abs/10.1080/00273171.2018.1454823

58. Bringmann LF, Vissers N, Wichers M, Geschwind N, Kuppens P, Peeters F, et

al. A Network Approach to Psychopathology: New Insights into Clinical

Longitudinal Data. PLoS One [Internet]. 2013 Apr 4 [cited 2022 Jun

27];8(4):e60188. Available from:

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0060188

11. FIGURE LEGEND

Figure 1

The study uses a prospective experience sampling design involving in vivo data gathering using survey and actigraphy. The participants are asked to engage with the data collection process over 7 consecutive days (8 nights) twice, six-months apart. An example data collection procedure in a single day is detailed in the box of dashed outline. The participants are prompted to complete a sleep diary in the morning and 3 daily surveys each day. The participants are also asked to wear an actigraph during the entire 7-day (8-night) period for each wave, generating objective estimates of sleep and physical activity. The timing of the diary and surveys is pre-specified. If a participant's typical wake time is 08:00, a prompt to complete the sleep diary will be sent at 08:30, then the first, second and third daily surveys at 11:00, 13:30 and 16:00.



Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

COVID Checklist

The checklist is administered by a member of the research team over the telephone once per person, per timepoint (T1 and T2). This is to ensure reduced risk of virus transmission and to ensure that the sleep, pain, mood and activity measured within the study are representative of their typical chronic pain and not influenced by COVID infection. The COVID checklist requires participants to answer three questions to determine any recent exposure:

1. Have you experienced any of the main COVID-19 symptoms in the last 48 hours?

2. In the last 7 days have you come into close contact with anyone who has tested positive for COVID-19 to your knowledge?

3. Are you or is anyone in your household/bubble currently self-isolating?

If a participant answers 'yes' to one or multiple questions, they will be asked to postpone their participation until they no longer test positive. Data obtained from the checklist will not be analysed as their purposes are for health and safety and to maintain data integrity.
BMJ Open

BMJ Open

Investigating Mental Defeat in Patients with Chronic Pain: Protocol for a Longitudinal Experience Sampling Study

Journal:	BMJ Open			
Manuscript ID	bmjopen-2022-066577.R1			
Article Type:	Protocol			
Date Submitted by the Author:	28-Dec-2022			
Complete List of Authors:	Gillett, Jenna; University of Warwick, Psychology Karadag, Paige; University of Warwick, Psychology Themelis, Kristy; University of Warwick, Psychology Li, Yu-Mei; Bielefeld University, Psychology Lemola, Sakari ; Bielefeld University, Psychology Balasubramanian, Shyam; University Hospitals Coventry and Warwickshire NHS Trust Singh, Swaran; University of Warwick Warwick Medical School, Mental Health and Wellbeing Tang, Nicole; University of Warwick, Psychology			
Primary Subject Heading :	Research methods			
Secondary Subject Heading: Mental health				
Keywords: PAIN MANAGEMENT, MENTAL HEALTH, STATISTICS & RESEARCH METHODS, COVID-19				
Note: The following files were submitted by the author for peer review, but cannot be converted to PDF. You must view these files (e.g. movies) online.				
actiwatch_video_supplementary_material.mp4				



Page 1 of 36

BMJ Open

3 4	1	TITLE: Investigating Mental Defeat in Patients with Chronic Pain: Protocol for a					
5 6	2	Longitudinal Experience Sampling Study					
7 8	3						
9 10 11	4	AUTHORS: Jenna L Gillett (PhD Researcher) ^{1*} , Paige Karadag (Research					
12 13	5	Assistant) ¹ *, Kristy Themelis (Post-Doctoral Research Fellow) ¹ , Yu-Mei Li (Post-					
14 15	6	Doctoral Research Fellow) ² , Sakari Lemola (Professor) ² , Shyam Balasubramanian					
16 17 18	7	(Consultant) ³ , Swaran Singh (Professor) ⁴ , Nicole KY Tang (Professor) ¹					
19 20	8						
21 22	9	¹ Department of Psychology, University of Warwick, Coventry, United Kingdom					
23 24	10	² Department of Psychology, Bielefeld University, Bielefeld, Germany					
25 26 27	11	³ University Hospital Coventry and Warwickshire NHS Trust, Coventry, United					
27 28 29	12	Kingdom					
30 31	4Warwick Medical School, University of Warwick, Coventry, United Kingdom						
32 33	14						
34 35 36	*Joint first authorship (equal contributions)						
37 38	16	6 ^a Corresponding Author: Nicole KY Tang, Email: <u>n.tang@warwick.ac.uk</u>					
39 40	17						
41 42	18	ORCID IDs:					
43 44 45	19	J.L. Gillett: 0000-0002-7115-9938					
46 47	20	P. Karadag: 0000-0003-2655-7109					
48 49 50 51 52	21	K. Themelis: 0000-0002-0022-5272					
	22	YM. Li: 0000-0002-4673-1082					
53 54	23	S. Lemola: 0000-0002-1314-6194					
55 56	24	S. Balasubramanian: 0000-0001-5149-3595					
57 58 59 60	25	N.K.Y. Tang: 0000-0001-7836-9965					

Page 2 of 36

BMJ	Open
-----	------

26	
27	ABSTRACT
28	Introduction: Previous qualitative and cross-sectional research has identified a
29	strong sense of mental defeat in people with chronic pain who also experience the
30	greatest levels of distress and disability. This study will adopt a longitudinal
31	experience sampling design to examine the within-person link between the sense of
32	mental defeat and distress and disability associated with chronic pain.
33	
34	Methods and Analysis: We aim to recruit 198 participants (aged 18-65 years) with
35	chronic pain, to complete two waves of experience sampling over 1 week, 6 months
36	apart (Time 1 and Time 2). During each wave of experience sampling, the
37	participants are asked to complete 3 short online surveys per day, to provide in-the-
38	moment ratings of mental defeat, pain, physical and social activity, stress, mood,
39	self-compassion, and attention using visual analogue scales (VAS). Sleep and
40	physical activity will be measured using a daily diary as well as with wrist-actigraphy
41	worn continuously by participants throughout each wave. Linear mixed models and
42	Gaussian graphical models will be fit to the data to: (1) examine the within-person,
43	day-to-day association of mental defeat with outcomes (i.e., pain, physical/social
44	activity, medication use and sleep) (2) examine the dynamic temporal and
45	contemporaneous networks of mental defeat with all outcomes and the hypothesised
46	mechanisms of outcomes (i.e., perceived stress, mood, attention, and self-
47	compassion).
48	
49	Ethics & Dissemination: The current protocol has been approved by the Health
50	Research Authority and West Midlands – Solihull Research Ethics Committee

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2				
3 4	51	(Reference Number: 17/WM0053). The study is being conducted in adherence with		
5 6	52	the Declaration of Helsinki, Warwick Standard Operating Procedures and applicable		
7 8	53	UK legislation.		
9 10 11	54	STRENGTHS AND LIMITATIONS OF THE STUDY:		
12 13	55	This study provides the first longitudinal investigation of mental defeat in		
14 15	56	chronic pain to shed light on its temporal links with outcomes.		
16 17 18	57	 A range of outcomes and hypothesised mechanisms will be assessed 		
19 20	58	including pain, physical and social activity, medication use, sleep, stress,		
21 22	59	mood, attention, and self-compassion. Measures are repeated over a one-		
23 24 25	60	week period, at two time-points each six-months apart.		
25 26 27	61	This study will use both self-reported and objective estimates of sleep and		
28 29	62	physical activity, via diaries and actigraphy longitudinally.		
30 31	63	• The research is done remotely, at the participant's convenience and within		
32 33 34	64	their natural environment.		
35 36	65	Considerations must be given to effects of participants' COVID exposure on		
37 38	66	recruitment, subsequent attrition, and possible findings despite having had		
39 40 41	67	appropriate COVID screening and health and safety procedures in place.		
42 43	(0			
44 45	08			
46 47				
48				
49 50				
51				
52				
53				
54				
55 56				
50				
58				
59				
60				

BMJ Open

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

701.INTRODUCTION

Chronic pain is characterised as pain that persists or recurs beyond 3 months (1). It is highly prevalent, affecting around 30% of the population worldwide (2-4). Chronic pain conditions, namely low back pain and headaches, are consistently the top causes of years lived with disability (2,5) and reduced quality of life (6). People with chronic pain are three times as likely to have depression and anxiety disorders (7) and twice as likely to present a risk of suicide compared to the general population (8). Whilst some individuals manage to cope with the pain, others struggle to maintain daily activities. Understanding the factors that determine whether an individual can feel and function well- despite persistent pain- is crucial to advancing non-pharmacological management approaches for chronic pain, which have so far had a modest impact (9).

A concept proposed to help explain differences in the experience of pain-related distress and disability is mental defeat; a cognitive construct characterised by negative self-appraisals in relation to pain (10,11). The concept of defeat has its theoretical underpinnings in the study of post-traumatic stress disorder (PTSD) (12-14) and depression (15,16), where it is respectively defined as the perceived loss of autonomy and a natural response to the loss of social status in a conflict situation. Empirical research has shown that a strong sense of mental defeat is associated with severe PTSD symptoms and poorer response to exposure treatment (12,14,17). The perception of defeat has also been shown to predict symptoms of depression independent of hopelessness (15), and has been implicated in psychological models of suicidal behaviour and suicidality (18-20).

Mental defeat in the context of chronic pain encapsulates people's
 Mental defeat in the context of chronic pain encapsulates people's
 psychological response to perceived threats of one's physical and psychological

Page 5 of 36

1

BMJ Open

5

2 3 4	95	autonomy. Daily experience of living with persistent and debilitating pain which does
5 6 7 8 9 10 11 12 13	96	not respond to treatment is thought to be a repeated trigger of mental defeat,
	97	prompting negative appraisals of self in relation to pain (21). Consistently, qualitative
	98	explorations of patient experience have revealed patients reporting "defeat of the
	99	mind" and "the pain is taking over", with the pain seen as "an enemy" that "belittles
14 15	100	[them] as a person" (11,22,23).
16 17 18	101	Using the Pain Self Perception Scale to measure mental defeat, it has been
19 20	102	found that treatment-seeking patients with chronic pain have elevated levels of
21 22	103	mental defeat compared to: patients with acute pain, patients with anxiety disorders,
23 24 25	104	community volunteers with chronic pain, community volunteers with acute pain and
25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45	105	pain-free volunteers (21). Mental defeat has also been found to be the predictor
	106	explaining the most variance in pain interference, depression, and psychological
	107	disability among chronic pain patients seeking specialist treatment, when compared
	108	to pain intensity, health anxiety, worry rumination, and pain catastrophising (11). It
	109	has moderate associations with sleep disturbances and functional disability (11) and
	110	negatively relates to pain self-efficacy even when anxiety, depression, pain
	111	catastrophising, and hopelessness are controlled for (24). Furthermore, mental
	112	defeat predicts suicide intent in patients with chronic pain above and beyond pain
	113	intensity (25). In pain-free volunteers, an activated sense of mental defeat appears to
46 47 48	114	operate independently from existing pain-related psychological constructs such as
48 49 50 51 52	115	pain catastrophising, in influencing mood and attentional disengagement from
	116	nociceptive stimuli (26). Together, these findings suggest how a person's self-
53 54	117	perception in relation to pain matters in terms of predicting and explaining outcomes.
55 56 57	118	However, most of the aforementioned studies of mental defeat in chronic pain
58 59 60	119	are cross-sectional in design, and more direct evidence is required to establish the

nal in design, and more direct evidence is required to establish the For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open

6

2 3	120	temporal and casual association implicated. This study will be the first to utilise
4 5	121	experience sampling methodology (ESM) involving <i>in vivo</i> data gathering (using
6 7 8	122	actigraphy, sleep diaries and daily online surveys) to examine the day-to-day
9 10	123	association between mental defeat, symptoms, distress, and disability associated
11 12	124	with chronic pain. Data will be collected over 7 days, allowing the study of any
13 14 15	125	temporal within-person relationships which may provide insight into clinically relevant
16 17	126	questions such as whether mental defeat will be followed by higher pain, increased
18 19	127	stress, greater attention to pain, increased medication usage, reduced physical and
20 21 22	128	social activity and poorer sleep. The experience sampling exercise is repeated at 6
23 24	129	months to investigate how these indices may change over time and translate into
25 26 27	130	distress and disability long-term. The primary objectives of this study are: (1)
28 29	131	examine the within-person, day-to-day association of mental defeat with outcomes
30 31	132	(i.e., pain, physical/social activity, medication use and sleep), and (2) examine the
32 33 34	133	dynamic temporal and contemporaneous networks of mental defeat with all
35 36	134	outcomes and the hypothesised mechanisms of outcomes (i.e., perceived stress,
37 38	135	mood, attention, and self-compassion).
39 40 41	136	Based on previous work (e.g. 11,21,25) we hypothesise that, for an
42 43	137	individual, a strong sense of mental defeat will be associated with subsequent
44 45	138	greater reports of pain, reduced physical and social activity, possible increased use
46 47 48 49 50 51 52	139	of medication, and poorer sleep. Examinations of the dynamic temporal and
	140	contemporaneous networks of mental defeat with mechanisms and outcomes are
	141	novel and exploratory.
54 55	142	
56 57	143	2. METHOD
58 59 60	144	2.1 Study Design

Page 7 of 36

1

2						
3 4	145	This study utilises a within-study design that uses an experience sampling methods				
5 6	146	(ESM) approach (27). As depicted in Figure 1, ESM are used to gather data				
7 8	147	prospectively over 1-week; at two-time points, each six months apart (T1 and T2).				
9 10 11	148	The length and frequency of assessment reflect our attempt to balance information				
12 13	149	needs with concerns of participation burden and possible attrition, participants are				
14 15	150	asked to continuously wear a medical-grade actigraphy device (MotionWatch 8 $^{ m C}$,				
16 17 18	151	manufactured by CamNTech Ltd) for 8 nights/7 days. They are asked to complete a				
19 20	152	sleep diary and respond to 3 short online surveys during the day. These surveys will				
21 22	153	provide in-the-moment measures of mental defeat, pain, medication use, physical				
23 24 25	154	activity and social activity, stress, mood, attention, and self-compassion using visual				
25 26 27	155	analogue scales (VAS).				
28 29	156					
30 31	157	*Insert Figure 1 about here*				
32 33 34	158					
35 36	159	2.2 Participants & Sample Size				
37 38	160	Participants are adults aged 18-65 living with chronic non-cancer pain that has been				
39 40	161	present or recurring for more than 3 months (28,29). Participant inclusion and				
41 42 43	162	exclusion criteria are outlined in Table 1.				
44 45	163					
46 47 48 49	164 165	Table 1. PARTICIPANT INCLUSION & EXCLUSION CRITERIA FOR PARTICIPATION Inclusion Criteria:				
50 51		\sim Aged between 18 - 65 (for focussing our study on working age nonulation)				
51 52		\sim Aged between 10 – 05 (10) locussing our study on working-age population).				
53		 Experience chronic non-cancer pain for at least 3 months. Stable treatment for duration of the study (6 months). 				
54		 Stable iteration for understanding and implementing the data collection 				
55		procedure)				
56 57		 Living in the UK (for postage of equipment) 				
58		 Be able to provide informed consent 				
59						
60						

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

8

3		Exclusion Criteria
4		► Have any significant comorbid neverintric (o.g., neverine), modical (o.g.,
5		Have any significant comorbid psychiatric (e.g., psychosis), medical (e.
6		coronary heart diseases), heurological (e.g., Alzheimer S, Parkinson S,
7		Epilepsy) or life-threatening conditions that would impact pain experience,
8		impede the ability to provide informed consent or complete the study.
9		Have any other significant comorbid sleep disorder, e.g., sleep appoea.
10		restless lea syndrome periodic limb movement disorder, parcolensy or
11		resultions registered and the principal of the research to the standard of the research to the standard with the standard sta
12		circadian mythm disorders, which in the opinion of the research team would
13		cofound the results of the study.
14		Have elective surgery or procedures requiring general anaesthetic during
15		the study
16		Have participated in another research study using an investigational
17		Thave participated in another research study using an investigational and the meet 0 meeths.
17		product in the past 3-months.
10	166	*Note: the examples given in the inclusion/exclusion criteria are not exhaustive and
19	167	participants' eligibility is assessed on a case-by-case basis by the research team.
20	168	
21	100	
22	1.60	
23	169	In terms of sample size calculation, based on running previous ESM studies of this
24		
25	170	kind (30) we aim to recruit 198 participants to factor in an anticipated 20% attrition at
26		
27	171	T2. This will give an estimated 159 participants who will complete the experience
28	1/1	12. This will give an estimated 156 participants who will complete the experience
29		
30	172	sampling procedure at both timepoints to generate up to 6636 temporally structured
31		
32	173	survey ratings for analysis (3 ratings x 7 days x 2 timepoints x 158 participants)
33	175	survey ratings for analysis (5 ratings x 7 days x 2 timepoints x 150 participants).
34		
35	174	There will be a maximum of 2528 observations of sleep data (8 nights of actigraphic
36		
37	175	data x 2 timepoints x 158 participants) and 7 days' of physical activity count data at
38		
30	176	30 second enach. This will give sufficient newer to perform the planned analyses
40	1/0	subsection epoch. This will give sufficient power to perform the planned analyses
40		
41	177	using Multilevel Mixed-Effects Models (31) and Graphical Gaussian Models (32).
42		
43	178	
44	170	
45	170	
46	1/9	2.3 Recruitment
47		
48	180	Recruitment of participants started in April 2021 and is expected to end in May 2023.
49		
50	101	A variety of recruitment methods are being used, including social media, the NIHP
51	101	A valiety of recruitment methods are being used, including social media, the Minix
52		
53	182	Clinical Research Network, public engagement events, and peer-led support groups.
54		
55	183	We are also using online recruitment platforms to capture individuals with chronic
56	105	
57	104	and with a statement interest to fell a section second to the second second second second second second second
58	184	pain with registered interest to take part in research. Finally, chronic pain patients at
59		
60		
~ -		

1 2

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

Table 2.

Measure

Key Variable of Interest

Pain-Related Measures

Mental defeat

2.4 Measures

2.4.1 Screening Questionnaire

2.4.2 Baseline Questionnaire

except for characterising the sample at baseline.

QUESTIONNAIRE MEASURES INCLUDED

1	
I	
2	
З	
2	
4	
5	
6	
-	
7	
8	
0	
9	
10	
11	
11	
12	
13	
11	
14	
15	
16	
17	
17	
18	
19	
20	
21	
22	
22	
23	
24	
25	
25	
26	
27	
20	
20	
29	
30	
21	
31	
32	
22	
22	
34	
35	
36	
50	
37	
38	
20	
59	
40	
41	
د ا	
42	
43	
44	
45	
45	
46	
47	
40	
48	
49	
50	
50	
51	
52	
50	
22	
54	
55	
EC.	
20	
57	
58	
50	
59	
60	

185 University Hospitals Coventry and Warwickshire are given information about the186 study during pain clinic appointments.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

9

A brief online screening questionnaire is administered to assess eligibility. To provide

the relevant information against the *a priori* inclusion and exclusion criteria, the

screening questionnaire determines basic demographics (e.g., age, sex, ethnicity,

employment status, education level) and health indicators (e.g., body mass index,

average alcohol intake, smoking status). It also checks for pain characteristics,

current treatment plans, e.g. plans for surgery in the next 6-months and current

the presence of any psychiatric, medical, neurological or sleep disorders.

participation in clinical trials. Lastly, it considers comorbid health conditions, including

Eligible participants are asked to complete a baseline questionnaire which includes

validated measures of variables related to mental defeat, pain, physical and social

activity, sleep, psychological states and quality of life (see Table 2 for full list). Data

from these questionnaires are not used in the planned analyses of the current study

Scale Used

Pain Self-Perception Scale (PSPS)(21)

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

	Pain intensity & interference	Brief Pain Inventory-Short Form (BPI- sf)(33)	
	Pain vigilance and awareness	Pain Vigilance & Awareness	
	Pain-related fear of movement	Tampa Scale of Kinesiophobia (TSK- 11)(35)	
	Patterns of activity (pain-specific)	Patterns of Activity Measure for Pain (POAM-P)(36)	
	Pain catastrophising Pain self-efficacy	Pain Catastrophizing Scale (PCS)(37) Pain Self-Efficacy Questionnaire (PSEQ)(38)	
	Physical & Social Activity Measures		
	Physical activity	International Physical Activity	
	Social activity	Questionnaire (IPAQ)(39) Social Activity Log (SAL)(40)	
	Sleep-Related Measure		
	Insomnia symptom severity	Insomnia Severity Index (ISI)(41)	
	Psychological States		
	Stress	Perceived Stress Scale (PSS)(42)	
	Anxiety & depression	Hospital Anxiety & Depression Scale (HADS)(43)	
	Suicidal behaviour	Suicidal Behaviour Questionnaire Revised (SBQ-R)(44)	
	Self-compassion	Self-Compassion Scale Short Form (SCS-sf)(45)	
	Quality of Life Measure		
	General health and quality of life	EQ-5D-5L(46)	
208	`	0	
209	2.4.3 Sleep Diary		
210	The morning section of the Consensus S	Sleep Diary (47) is administered daily	
211	throughout the tracking period to collect self-reported information on sleep. The		
212	sleep diary asks participants what time t	hey went to bed, what time they attempted to	
213	go to sleep, how long it took them to fall asleep (sleep onset latency), how many		
214	times did they wake up from sleep (not i	ncluding final awakening), final wake up	
215	time, what time did they get out of bed, t	total sleep duration (hours and minutes),	
216	perceived sleep-quality and how rested	or refreshed they felt after waking.	

217 Participants can also provide additional information that they feel is relevant to their

BMJ Open

sleep. We added two extra questions to the sleep diary to obtain in-the-moment ratings of pain and mood upon waking. These possible covariates are assessed via two VAS both ranging from 0-10, whereby for pain 0= no pain at all and 10= worst pain imaginable and for mood 0= very bad and 10= very good.

2.4.4 Daily Survey

The daily survey allows participants to provide self-report ratings at multiple points throughout each day. We use adapted or proxy measures as well as shortened versions of original scales to decrease participant burden and determine momentary assessments of mental defeat, pain, medication use, physical and social activity, stress, mood, attention, and self-compassion (see Figure 1 for a schedule of administration). As part of the PPI piloting process, the selected questions and proxy measures were approved by our PPI representatives (two people with lived experience of chronic pain). The surveys are short (<5 minutes completion time) and are equally spaced 2.5 hours apart to capture experiences at different time points throughout the day. The surveys are sent out following a choice of pre-determined schedules to match participants' typical sleep-wake patterns. The earliest schedule starts with a sleep diary at 06:30 and the first daily survey commences at 09:00, whereas the latest schedule starts with a sleep diary at 13:30 and the first daily survey commences at 16:00. The timing of these measures avoids unsociable hours, as no prompts arrive between the hours of 23:00 and 06:00 inclusive. We use Survey Signal to send out auto-prompts at specified times via SMS to participants' smartphones. This enables accessibility for participants to complete

surveys in a timely fashion, while remaining convenient, and does not require an app

download or adjusted personal mobile settings. The surveys are administered,

BMJ Open

recorded, and returned via Qualtrics and are time-stamped at the time of

244 commencement and completion. The daily surveys comprise multiple VAS with

245 varying left to right anchors, as shown in Table 3.

10 246

¹¹ 247 **Table 3.**

248	DAILY SURVEY SELF-REPORT RATING SCALES						
	Construct	Item (measure)	Scale	Anchors			
	Mental defeat	Since waking up today, how much has the pain brought back to life memories of times when you felt the pain had taken over?	0 – 10	0= not at all to 10= very much so			
	Pain intensity	What is your current pain level?	0 – 10	0 = no pain to 10 = worst pain imaginable			
	Pain interference	 Since waking up today, how much has your pain impacted on a) Your daily routine (including work)? b) Your relationship(s)? c) How you think or feel about the future? d) How you think or feel about yourself? 	0 – 10	0= not much impact/interference to 10 = a great deal of impact/interference			
	Medication use	Since waking up today, would you say that you have taken more or less medication than usual?	-5 - 5	-5= a lot less than usual, 0 = no difference, 5 = a lot more than usual			
	Physical activity	Since waking up today, how physically active have you been?	0 – 10	0= not physically active at all to 10= very physically active			
	Social activity	Since waking up today, how socially engaged have you been?	0 – 10	0= not socially engaged at all to 10= very socially engaged			
	Stress	What is your current stress level?	0 – 10	0= no stress at all to 10= highest level of stress possible			
	Mood	What is your current mood?	0 – 10	0= very bad to 10 = very good			

26

27

28

29 30

31

34

36

43

59

13

	15		
Attention to pain	Since waking up today, how much of the time have you been thinking about your pain?	0 – 10	0= none of the time to 10= a great deal of the time
Focus of attention	Since waking up today, has the focus of your attention been a) Inward or outward b) On the body or mind	0 – 10	0 = inward to 10 outward 0 = body to 10= mind
Self- compassion	Since waking up today, how kinda) to yourself have you been?b) to others have you been?	0 – 10	0= not at all to 10= very much so

Note. VAS questions with corresponding anchors that are presented in Survey 1 are summarised
above. These questions appear identically in Surveys 2 and 3, except instead of starting questions
with "since waking up today..." in Surveys 2 and 3 each question begins "in the last 2.5 hours...".

253 **2.4.5 Actigraphy**

Actigraphs are light, compact accelerometer-based devices that have been used to

- ³⁵ 255 generate objective estimates of sleep parameters for several decades (48).
- $\frac{37}{38}$ 256 Actigraphy has been well-evidenced as a suitable methodology for non-intrusive at-
- $^{39}_{40}$ 257 home sleep assessment (49–51). Although polysomnography continues to be
- 41
 42 258 considered the gold standard for sleep recording, wrist-actigraphy has the advantage
- ⁴⁴ 259 of offering cost-effective continuous recording in participants' home environment
- $^{46}_{47}$ 260 (52). Thus providing more ecologically valid information compared to
- ⁴⁸ 49 261 polysomnography (52).
- 50 51 262 For the present study, MotionWatch 8© actigraphs are worn by participants on 52
- $^{53}_{54}$ 263 their non-dominant wrist during the study. The MotionWatch is a medical-grade tri-
- ⁵⁵ 264 axial actigraphy device containing a piezoelectric accelerometer to record duration,
- ⁵⁷ ⁵⁸ 265 integration, and number of movements in all directions. This data enables the
- ⁶⁰ 266 research team to chart sleep and physical activity across the experience sampling

Page 14 of 36

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

periods that are then downloaded for analysis using MotionWare© software
(Cambridge Neurotechnology Ltd., Cambridge, UK) with validated algorithms. The
key sleep parameters we are interested in are sleep efficiency (SE) and total sleep
time (TST). The key physical activity parameter is total activity counts tabulated by
week, day, and/or hour.

2.5 Procedure

To participate, individuals respond to a study advert via phone, email or by following a direct link to the information leaflet. Interested participants are required to complete the screening questionnaire and contact information form, following which a member of the research team determines eligibility to the study by checking against the inclusion/exclusion criteria. Individuals who meet the inclusion criteria are informed of their eligibility via email and invited to participate. Individuals who do not meet the inclusion criteria are informed via email that they are not eligible, thanked and debriefed.

Eligible participants that agree to participate are sent a link to an online consent form to complete via Qualtrics. Once informed consent has been obtained, participants have a phone call with a member of the research team to arrange their participation and highlight some key training points for the study. All participants receive the study materials (an invitation letter, a cleaned and packaged MotionWatch for borrowed use, two individually wrapped disinfectant wipes, an addressed, pre-paid return envelope, and an information booklet) via UK postal delivery. To accompany the information booklet, participants are emailed a link to an instructional video (see supplementary file 1) demonstrating how to use the MotionWatch devices appropriately and reiterating the schedule of

Page 15 of 36

BMJ Open

measurement/engagement required during participation. Participants are instructed to wear the MotionWatch continuously for the 7-day experience sampling period and are required to press an event marker on the device when they plan to go to sleep and when they get out of bed, following their main sleep period. Participants are also asked to answer the sleep diary and three short surveys each day.

The timing of the daily surveys/sleep diary are individually anchored by participants' typical sleep-wake patterns, to accommodate and control for variations in individuals' circadian rhythms. For example, if a participant indicates that they usually wake at 08:00, a typical day during the experience sampling period on this schedule would be as follows: upon getting out of bed, the participant presses the event marker on the MotionWatch and will receive the first text message (with a link to the sleep diary) at 08:30 – allowing them to report their sleep experiences as soon as practical after waking. Throughout the day, the participant will receive three further text message prompts, each containing a link to the short online survey. Survey 1 (S1) is received at 11:00, survey 2 (S2) at 13:30 and survey 3 (S3) at 15:00. The links to each survey remains open for 2.5 hours, before expiring at the time the following survey is triggered. Finally, the participant will be required to press the event marker at "lights out" or when beginning trying to sleep. This process is identical for each day in the experience sampling period. After the final awakening on the last day, the participant removes the MotionWatch, and packages it in the box ready for return-postage to the Lab. The MotionWatch data is processed on-site at the Lab, before being formatted into a personalised breakdown for the participant, which is emailed to them along with a gift voucher within two weeks of receipt of the returned equipment. This procedure is repeated in its entirety for the follow-up T2 assessment. The debrief is administered upon study completion.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

2.6 Participant Reimbursement To thank the participants for their time and participation, they are given a £10 gift voucher for each timepoint they complete. Additionally, participants are provided with a personalised breakdown of their actigraphy data created by the research team. No evaluative feedback on sleep quality and physical activity patterns is given. 2.7 Adverse Event Recording and Management This is a low-risk observational study, and no major adverse events are anticipated. We offer health and safety training at the outset, instructing participants not to respond to survey text messages if it is not safe to do so, e.g., when driving, operating machinery, or crossing the road. Before participation commences, participants are instructed to report any adverse events that occur during the assessment periods to the research team. Adverse events that are related to the study and/or unrelated adverse events are recorded and reported to the study sponsor according to reporting requirements. Unrelated and expected adverse events may include but are not limited to illness, hospitalisation or day-surgery that occurs during the assessment period. An adverse event that a small number of participants may experience is discomfort or irritation caused by wearing the MotionWatch. Before participants begin the study, we advise them to inform the researcher if they experience any skin irritation. If the irritation is very mild and they wish to continue, we recommend placing a small piece of tissue underneath the watch or to place the silicon strap on top of their sleeve to avoid direct skin contact. In the unlikely event of an unexpected adverse event that is deemed to be severe and related to the study, the research team would immediately

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

3 4	342	pause the study and send an expedited report to the study sponsor. Events will be
5 6 7	343	followed up until they are resolved or when a final outcome has been reached.
7 8 9	344	
10 11	345	2.8 Patient and Public Involvement
12 13 14	346	This protocol has been developed in partnership with two patient representatives
14 15 16	347	with lived experience of chronic pain. One representative (PR) provided feedback on
17 18	348	participant-facing materials and piloted the MotionWatch for at-home use. DD
19 20	349	participated in study-related procedures and also commented on the manuscript for
21 22 23	350	readability.
24 25	351	
26 27	352	2.9 COVID Related Considerations
28 29 30	353	To enable the study to take place during the COVID-19 pandemic, while adhering to
31 32	354	governmental and institutional COVID-19 guidance, the operational aspects of the
33 34	355	protocol have been adapted for remote participation. The MotionWatch devices are
35 36 27	356	all sanitised, prepared and packaged for participation in a lab environment. A short
37 38 39	357	COVID checklist has been implemented before each wave of tracking (see
40 41	358	supplementary file 2).
42 43	359	
44 45 46	360	3. DATA MANAGEMENT PLAN
47 48	361	The study data collected from the questionnaire, sleep diary and daily surveys will be
49 50	362	stored securely on Qualtrics and subsequently downloaded as password protected
51 52 53	363	databases to undergo data quality checks and pseudo-anonymisation by the
55 54 55	364	research team. Access to these databases will be restricted to approved members of
56 57	365	the research team. Once data completeness and quality are verified, electronic data
58 59 60	366	on Qualtrics will be deleted.

Page 18 of 36

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

Actigraphic data collected using MotionWatch 8© are downloaded using Motionware© software upon each watch's return to the lab. The downloaded data are saved via their assigned ID number and will be held securely and separately from the study data.

The Chief Investigator (NT) of the project will act as the data controller. All data generated by the research programme will be analysed by the research team either on site at the University of Warwick or in a private workspace in the event of remote-working, as per the University's Off-Campus Working Policy. In line with the University's Research Code of Conduct, data will be retained in electronic format for at least 10 years from the date of any publication that is based upon it.

> 4. STATISTICAL METHODS

All participants who meet eligibility criteria will be included in analyses; including those who wish to withdraw from the study but consent to having any data already collected analysed. Those who withdraw and do not consent to the data being analysed will be excluded from analyses.

Descriptive statistics will be used to characterise the sample based on information from the screening and baseline questionnaires. Means and standard deviations/95% confidence intervals will be reported for continuous variables, whereas frequencies and percentages will be used for reporting categorical variables.

To evaluate the within-person temporal relationship between mental defeat (predictor) and pain, physical and social activity, medication use and sleep (outcomes), we will pool the daily survey ratings from all participants across waves of assessment. Linear mixed models with a time-lagged design will be fit to the data.

Page 19 of 36

BMJ Open

We will fit one model for each outcome. For each analysis, we will first estimate a maximal random effects model with all random slopes and random intercepts (for 'time of day [survey 1, 2, 3]', 'day [1, 2, 3, 4, 5, 6, 7]' and 'wave [1, 2]') and successively simplify the random effect structure until the model converges. Nested comparisons will be made between the final models with the intercepts-only models. The significance of each model will be assessed using a likelihood ratio test (LRT). P-values will be adjusted using false discovery rate to account for alpha error accumulation (FDR; (53)). The best fitting model will be determined using Aikaike Information Criteria (AIC) (54,55) and Bayesian Information Criteria (BIC) (56), where lower values of the AIC and BIC indicate a better fit. As secondary analyses, we will repeat the above analyses with the hypothesised mechanisms of outcomes (stress, mood, attention, self-compassion) as the dependent variables. Both the statistical software SPSS (IBM Corp., Armonk, NY, USA) and the "Ime4" package (57) for R (58) will be used.

66406To explore the within-individual temporal and contemporaneous relationships407as well as between-individual relationships between mental defeat and the outcomes408and hypothesised mechanisms of interest, we will use Gaussian graphical models409(GGM; (32)). To obtain sufficient statistical power for within-in individual variances in410the GGMs, it is recommended to have more than 20 measurements and at least 20411pairs of comparisons per participant (59). The design of the current study will yield41221 measurements per participant per wave. That will give 20 pairs of comparisons413for modelling changes across days, 14 pairs of comparisons for modelling changes414within day, and 7 pairs of comparisons for modelling changes at different times of the415day. We will therefore not seek to model changes at different times of the day, but to

Page 20 of 36

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

BMJ Open

focus on modelling changes across and within day by pooling together data from both waves of assessment. We will use the mIVAR (Version 0.3.2) package (59,60), or similarly suitable but more up-to-date packages, for R (58) to analyse the multivariate time series data. We will report three kinds of network; temporal (to indicate whether a variable predicts another variable (or itself) at the next measurement point, controlling for all other variables in the network at the previous measurement point), contemporaneous (to indicate the within-person relationships between variables, having adjusted for the effect of all variables in the network and the temporal effects) and between-person (to indicate relationships between person-means of variables, partialling out the effect of all other variables in the network). Additional secondary analyses will be performed for research questions other than the 2 main ones stated here. Any deviation(s) from the original statistical plan will be described and justified in our subsequent reportings.

5. LIMITATIONS

Although this study design provides the first prospective investigation of mental defeat in chronic pain, more research is needed to evidence any potential causality of key mechanisms and outcomes. As in previous experience sampling studies that measure sleep, we expect some minor discrepancies between actigraphy and diary data (61) due to memory biases when self-reporting on one's own sleep estimations. which is common in this type of research. In this study we will cross-check for any discrepancies between diary and objective sleep measures and will run sensitivity analyses to determine effective interpretation in subsequent analyses. Furthermore, participants are required to undergo some short training on how to participate in the

Page 21 of 36

 BMJ Open

study and use the equipment (actigraphy devices) effectively, which will naturally
result in some errors and inconsistencies in individual engagement levels, so we are
expecting some data to be lost to missingness. Finally, considerations must be given
to effects of participants' COVID exposure on recruitment, subsequent attrition, and
possible findings despite having had appropriate COVID screening and health and
safety procedures in place.

7 447

6. ETHICS & DISSEMINATION

This research forms part of the wider MRC-funded Warwick Study of Mental Defeat in Chronic Pain ("WITHIN" Study). The current protocol has been approved by the Health Research Authority and West Midlands – Solihull Research Ethics Committee (Reference Number: 17/WM0053, p, IRAS project ID: 223190). The University of Warwick (Research Impact Services, University of Warwick, Coventry, CV4 7AL) acts as the Sponsor for the study. The study is being conducted in adherence with the Declaration of Helsinki, Warwick Standard Operating Procedures and applicable UK legislation. Results from this study will be written as reports, to be disseminated in peer-reviewed journals, at conferences and patient and public engagement events.

460 7. AUTHOR'S CONTRIBUTIONS AND ACKNOWLEDGEMENTS

- ⁹ 461 **6.1 Autho**
 - 6.1 Authors' Contributions

462 NT conceived the research idea and developed the theory and plan for this study. JG
463 and PK are joint first author as they contributed equally to all aspects of the study
464 and are responsible for implementing the protocol, creating study materials, data
465 acquisition and management and drafting the original manuscript. KT and NT are

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

responsible for critical revisions of the manuscript. All authors (JG, PK, KT, Y-ML,

SL, SB, SS, NT) contributed to the study development and reviewed, commented,

and approved the manuscript.

6.2 Acknowledgements

The authors would like to thank all the participants who are involved in the study and the UK chronic pain charities who have shared our study on relevant webpages and social media platforms. We would also like to thank our PPI representatives (PR & DD) for their input into the study design and feasibility, including Debra Dulake (DD) who also commented on the manuscript. Finally, we would like to thank Michelle Pun, Emily Ashton and Chloe Osei-Cobbana who have supported the data collection process under the Psychology Research Skills Development Scheme (PRSDS) at . P. C. the University of Warwick.

8. COMPETING INTERESTS

The authors have no competing interests.

9. FUNDING

This protocol is part of a wider study (Warwick Study of Mental Defeat in Chronic

Pain that is supported by Medical Research Council (MRC) grant number:

MR/S026185/1 to NKYT. For the purpose of open access, the corresponding author

has applied a Creative Commons Attribution (CC BY) licence (where permitted by

UKRI, 'Open Government Licence' or 'Creative Commons Attribution No-derivatives

(CC BY-ND) licence' may be stated instead) to any Author Accepted Manuscript

version arising from this submission. JLG was funded by the University of Warwick Page 23 of 36

23

1 2 3 4 5 6 7
8 9 10 11 12
13 14 15 16 17
18 19 20 21 22
23 24 25 26 27
28 29 30 31 32
33 34 35 36 37
38 39 40 41 42
43 44 45 46 47
48 49 50 51 52
53 54 55 56

491 Departmental PhD Fellowship, under the supervision of NKYT. The funders have no 492 role in study design, data collection and analysis, decision to publish or preparation 493 of this manuscript. 494 495 **10. DATA SHARING STATEMENT** 496 Once available, cleaned, anonymised data generated from this study will be made 497 available on open-access repository. 498 499 **11. REFERENCES** 500 1. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. Chronic 501 pain as a symptom or a disease: The IASP Classification of Chronic Pain for 502 the International Classification of Diseases (ICD-11) [Internet]. Vol. 160, Pain. 503 Lippincott Williams and Wilkins; 2019 [cited 2022 Jun 14]. p. 19–27. Available 504 from: 505 https://journals.lww.com/pain/Fulltext/2019/01000/Chronic pain as a sympto m or a disease the IASP.3.aspx 506 507 2. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 508 509 354 diseases and injuries for 195 countries and territories, 1990–2017: a 510 systematic analysis for the Global Burden of Disease Study 2017. Lancet. 511 2018 Nov 10:392(10159):1789-858. Dahlhamer J, Lucas J, Zelaya, C, Nahin R, Mackey S, DeBar L, et al. 512 3. 513 Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016. Morb Mortal Wkly Rep [Internet]. 2018 Sep 9 [cited 2022 514

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

⁵⁸ 515 Jun 14];67(36):1001–6. Available from: /pmc/articles/PMC6146950/

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

24

2			
- 3 4	516	4.	Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best
5 6	517		practices, and new advances [Internet]. Vol. 397, The Lancet. Elsevier; 2021
7 8 0	518		[cited 2022 Jun 14]. p. 2082–97. Available from:
9 10 11	519		http://www.thelancet.com/article/S0140673621003937/fulltext
12 13	520	5.	Vos T, Abajobir AA, Abbafati C, Abbas KM, Abate KH, Abd-Allah F, et al.
14 15	521		Global, regional, and national incidence, prevalence, and years lived with
16 17 18	522		disability for 328 diseases and injuries for 195 countries, 1990-2016: A
19 20	523		systematic analysis for the Global Burden of Disease Study 2016. Lancet
21 22	524		[Internet]. 2017 Sep 16 [cited 2022 Jun 29];390(10100):1211–59. Available
23 24 25	525		from: https://research.polyu.edu.hk/en/publications/global-regional-and-
25 26 27	526		national-incidence-prevalence-and-years-lived
27 28 29 30	527	6.	Fernández A, Saameño JÁB, Pinto-Meza A, Luciano JV, Autonell J, Palao D,
30 31 22	528		et al. Burden of chronic physical conditions and mental disorders in primary
32 33 34	529		care. Br J Psychiatry [Internet]. 2010 Apr [cited 2022 Jun 14];196(4):302–9.
35 36	530		Available from: https://www.cambridge.org/core/journals/the-british-journal-of-
37 38	531		psychiatry/article/burden-of-chronic-physical-conditions-and-mental-disorders-
39 40 41	532		in-primary-care/1F431966FA03440CA86EE7B2B2028FB6
42 43	533	7.	Von Korff M, Crane P, Lane M, Miglioretti DL, Simon G, Saunders K, et al.
44 45	534		Chronic spinal pain and physical-mental comorbidity in the United States:
46 47	535		Results from the national comorbidity survey replication. Pain [Internet]. 2005
48 49 50	536		Feb [cited 2022 Jun 28];113(3):331–9. Available from:
51 52	537		https://journals.lww.com/pain/Fulltext/2005/02000/Chronic_spinal_pain_and_p
53 54	538		hysical_mental.13.aspx
55 56 57	539	8.	Tang NKY, Crane C. Suicidality in chronic pain: A review of the prevalence,
58 59	540		risk factors and psychological links [Internet]. Vol. 36, Psychological Medicine.
60			

Page 25 of 36

1

2 3	541		Cambridge University Press; 2006 [cited 2022 Jun 14]. p. 575–86. Available
4 5 7 8 9 10	542		from: https://www.cambridge.org/core/journals/psychological-
	543		medicine/article/abs/suicidality-in-chronic-pain-a-review-of-the-prevalence-risk-
	544		factors-and-psychological-links/D3093AA52A611348B8F90CF0972380C5
11 12 13	545	9.	Williams AC d. C, Fisher E, Hearn L, Eccleston C. Psychological therapies for
14 15	546		the management of chronic pain (excluding headache) in adults [Internet]. Vol.
16 17	547		2020, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd;
18 19 20	548		2020 [cited 2022 Jun 14]. Available from:
20 21 22	549		https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007407.pub4/
22 23 24 25 26 27	550		full
	551	10.	Tang NKY, Salkovskis PM, Hanna M. Mental Defeat in Chronic Pain: Initial
27 28 29	552		Exploration of the Concept. Clin J Pain [Internet]. 2007 Mar [cited 2020 Apr
30 31	553		16];23(3):222–32. Available from: http://journals.lww.com/00002508-
32 33	554		200703000-00005
34 35 36 37 38	555	11.	Tang NKY, Goodchild CE, Hester J, Salkovskis PM. Mental defeat is linked to
	556		interference, distress and disability in chronic pain. Pain. 2010 Jun
39 40	557		1;149(3):547–54.
41 42 43	558	12.	Ehlers A, Maercker A, Boos A. Posttraumatic stress disorder following political
44 45	559		imprisonment: The role of mental defeat, alienation, and perceived permanent
46 47	560		change. J Abnorm Psychol [Internet]. 2000 [cited 2022 Jun 28];109(1):45–55.
48 49 50	561		Available from: /record/2000-13847-006
50 51 52	562	13.	Dunmore E, Clark DM, Ehlers A. A prospective investigation of the role of
53 54	563		cognitive factors in persistent Posttraumatic Stress Disorder ({PTSD}) after
55 56 57	564		physical or sexual assault. Behav Res Ther. 2001 Sep;39(9):1063–84.
57 58 59	565	14.	Dunmore E, Clark DM, Ehlers A. Cognitive factors involved in the onset and
60			

Page 26 of 36

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

26

2 3	566		maintenance of posttraumatic stress disorder (PTSD) after physical or sexual
4 5 6	567		assault. Behav Res Ther. 1999 Sep 1;37(9):809–29.
7 8 9 10 11 12 13 14 15 16 17 18	568	15.	Gilbert P, Allan S. The role of defeat and entrapment (arrested flight) in
	569		depression: An exploration of an evolutionary view. Psychol Med [Internet].
	570		1998 [cited 2022 Jun 14];28(3):585–98. Available from:
	571		https://www.cambridge.org/core/journals/psychological-
	572		medicine/article/abs/role-of-defeat-and-entrapment-arrested-flight-in-
19 20	573		depression-an-exploration-of-an-evolutionary-
21 22	574		view/A28C75514B33418F797269B1C276AC87
23 24 25	575	16.	Price J, Sloman L, Gardner R, Gilbert P, Rohde P. The social competition
26 27	576		hypothesis of depression [Internet]. Vol. 164, British Journal of Psychiatry.
28 29	577		Cambridge University Press; 1994 [cited 2022 Jun 14]. p. 309–15. Available
30 31 32	578		from: https://www.cambridge.org/core/journals/the-british-journal-of-
33 34	579		psychiatry/article/abs/social-competition-hypothesis-of-
34 35 36 37 38 30	580		depression/18622D076771AB200A26D318AF52A1D9
	581	17.	Ehlers A, Clark DM, Dunmore E, Jaycox L, Meadows E, Foa EB. Predicting
39 40 41	582		response to exposure treatment in PTSD: The role of mental defeat and
42 43	583		alienation. J Trauma Stress [Internet]. 1998 Jul 1 [cited 2022 Jun
44 45	584		28];11(3):457–71. Available from:
46 47 48	585		https://onlinelibrary.wiley.com/doi/full/10.1023/A%3A1024448511504
49 50	586	18.	Williams M. Cry of Pain: Understanding Suicide and the Suicidal Mind
51 52	587		[Internet]. 2014 [cited 2022 Jun 14]. 304 p. Available from:
53 54 55	588		https://books.google.co.uk/books?hl=en&lr=&id=msamAgAAQBAJ&oi=fnd&pg
56 57	589		=PT6&dq=+Williams,+M.+(2014).+Cry+of+pain:+understanding+suicide+and+t
58 59 60	590		he+suicidal+mind.+Hachette+UK.&ots=ssXWHmmFa7&sig=k3HIS7rgmKO0C

Page 27 of 36

1

BMJ Open

2 3 4 5 6	591		XiZiu5yLb4FkBA&redir_esc=y#v=onepage&q=Williams%2C M.
	592	19.	O'Connor RC, Kirtley OJ. The integrated motivational-volitional model of
7 8	593		suicidal behaviour [Internet]. Vol. 373, Philosophical Transactions of the Royal
9 10 11 12 13 14 15	594		Society B: Biological Sciences. The Royal Society; 2018 [cited 2022 Jun 14].
	595		Available from: https://royalsocietypublishing.org/doi/10.1098/rstb.2017.0268
	596	20.	Johnson J, Gooding PA, Wood AM, Tarrier N. Resilience as positive coping
16 17 18	597		appraisals: Testing the schematic appraisals model of suicide (SAMS). Behav
19 20	598		Res Ther [Internet]. 2010 Mar 1 [cited 2020 Mar 25];48(3):179–86. Available
21 22	599		from:
23 24 25	600		https://reader.elsevier.com/reader/sd/pii/S0005796709002484?token=047BFC
26 27	601		4DC2AA4BAC774ED9741F8C3365F5796A2CDB6555ABD4E520173D20517
28 29	602		0BFF3942B9E193578519667E13A37C052&originRegion=eu-west-
30 31 32 33 34 35 36 37 38 39 40 41	603		1&originCreation=20211006105621
	604	21.	Tang NKY, Salkovskis PM, Hanna M. Mental defeat in chronic pain: Initial
	605		exploration of the concept. Clin J Pain [Internet]. 2007 Mar [cited 2022 Jun
	606		14];23(3):222–32. Available from:
	607		https://journals.lww.com/clinicalpain/Fulltext/2007/03000/Mental_Defeat_in_Ch
42 43	608		ronic_Pain_Initial_Exploration.5.aspx
44 45	609	22.	Smith JA, Osborn M. Pain as an assault on the self: An interpretative
46 47 48	610		phenomenological analysis of the psychological impact of chronic benign low
49 50	611		back pain. Psychol Heal [Internet]. 2007 Jul [cited 2022 Jun 14];22(5):517–34.
51 52	612		Available from:
53 54 55	613		https://www.tandfonline.com/doi/abs/10.1080/14768320600941756
56 57	614	23.	Tang NKY, Salkovskis PM, Hodges A, Soong E, Hanna MH, Hester J. Chronic
58 59 60	615		pain syndrome associated with health anxiety: A qualitative thematic

2 3 4	616		comparison between pain patients with high and low health anxiety. Br J Clin
5 6 7	617		Psychol [Internet]. 2009 Mar 1 [cited 2022 Jun 14];48(1):1–20. Available from:
7 8	618		https://onlinelibrary.wiley.com/doi/full/10.1348/014466508X336167
9 10 11 12	619	24.	Hazeldine-Baker CE, Salkovskis PM, Osborn M, Gauntlett-Gilbert J.
12 13	620		Understanding the link between feelings of mental defeat, self-efficacy and the
14 15	621		experience of chronic pain. Br J Pain [Internet]. 2018 May 16 [cited 2022 Jun
16 17 18	622		14];12(2):87–94. Available from:
19 20 21	623		http://www.ncbi.nlm.nih.gov/pubmed/29796260
21 22	624	25.	Tang NKY, Beckwith P, Ashworth P. Mental defeat is associated with suicide
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41	625		intent in patients with chronic pain. Clin J Pain. 2016;32(5):411–9.
	626	26.	Collard VEJ, Gillett JL, Themelis K, Tang NKY. An exploratory investigation
	627		into the effects of mental defeat on pain threshold, pain rating, pain
	628		anticipation, and mood. Curr Psychol [Internet]. 2021 Mar 10 [cited 2022 Jun
	629		14];1–12. Available from: https://link.springer.com/article/10.1007/s12144-021-
	630		01548-3
	631	27.	Larson R, Csikszentmihalyi M. The experience sampling method. In: Flow and
	632		the Foundations of Positive Psychology: The Collected Works of Mihaly
42 43	633		Csikszentmihalyi [Internet]. Springer Netherlands; 2014 [cited 2022 Dec 9]. p.
43 44 45	634		21–34. Available from: https://link.springer.com/chapter/10.1007/978-94-017-
46 47 48	635		9088-8_2
49 50	636	28.	Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised
51 52	637		International Association for the Study of Pain definition of pain: concepts,
53 54 55	638		challenges, and compromises [Internet]. Vol. 161, Pain. NIH Public Access;
56 57	639		2020 [cited 2022 Jun 14]. p. 1976–82. Available from:
58 59 60	640		/pmc/articles/PMC7680716/

Page 29 of 36

1

2			
3 4	641	29.	NICE. Chronic pain (primary and secondary) in over 16s: assessment of all
5 6	642		chronic pain and management of chronic primary pain [Internet]. NICE
7 8	643		Guidelines. 2021 [cited 2022 Jun 14]. NICE guideline [NG193]. Available from:
9 10 11	644		https://www.ncbi.nlm.nih.gov/books/NBK569983/bin/niceng193er6_bm1.pdf
12 13	645	30.	Tang NKY, Goodchild CE, Sanborn AN, Howard J, Salkovskis PM.
14 15	646		Deciphering the temporal link between pain and sleep in a heterogeneous
16 17 18	647		chronic pain patient sample: a multilevel daily process study. Sleep [Internet].
19 20	648		2012 May 1 [cited 2021 Nov 10];35(5):675–87. Available from:
21 22	649		https://pubmed.ncbi.nlm.nih.gov/22547894/
23 24 25	650	31.	Magezi D a. Linear mixed-effects models for within-participant psychology
25 26 27	651		experiments: an introductory tutorial and free, graphical user interface
28 29	652		(LMMgui). Front Psychol [Internet]. 2015;6(January):1–7. Available from:
30 31	653		http://journal.frontiersin.org/Journal/10.3389/fpsyg.2015.00002/abstract
32 33 34	654	32.	Epskamp S, Borsboom D, Fried EI. Estimating psychological networks and
35 36	655		their accuracy: A tutorial paper. Behav Res Methods [Internet]. 2018 Feb 1
37 38	656		[cited 2022 Jun 14];50(1):195–212. Available from:
39 40 41	657		https://link.springer.com/article/10.3758/s13428-017-0862-1
42 43	658	33.	Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain
44 45	659		Inventory. [Internet]. Vol. 23, Annals of the Academy of Medicine, Singapore.
46 47 48	660		1994 [cited 2022 Jun 14]. p. 129–38. Available from:
40 49 50	661		https://europepmc.org/article/med/8080219
51 52	662	34.	Roelofs J, Peters ML, McCracken L, Vlaeyen JWS. The pain vigilance and
53 54	663		awareness questionnaire (PVAQ): Further psychometric evaluation in
55 56 57	664		fibromyalgia and other chronic pain syndromes. Pain. 2003 Feb 1;101(3):299-
58 59	665		306.
00			

Page 30 of 36

BMJ Open

30

2 3	666	35.	Woby SR, Roach NK, Urmston M, Watson PJ. Psychometric properties of the
4 5 6	667		TSK-11: A shortened version of the Tampa Scale for Kinesiophobia. Pain.
7 8 9 10 11 12	668		2005 Sep 1;117(1–2):137–44.
	669	36.	Cane D, Nielson WR, McCarthy M, Mazmanian D. Pain-related activity
12 13	670		patterns: Measurement, interrelationships, and associations with psychosocial
14 15	671		functioning. Clin J Pain [Internet]. 2013 May [cited 2022 Jun 14];29(5):435–42.
16 17 18	672		Available from:
19 20 21	673		https://journals.lww.com/clinicalpain/Fulltext/2013/05000/Pain_related_Activity
21 22	674		_PatternsMeasurement,.8.aspx
23 24 25	675	37.	Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale:
25 26 27 28 29 30 31 32 33 34 35 36	676		Development and Validation. Psychol Assess. 1995;7(4):524–32.
	677	38.	Nicholas MK. The pain self-efficacy questionnaire: Taking pain into account.
	678		Eur J Pain. 2007 Feb 1;11(2):153–63.
	679	39.	Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et
	680		al. International physical activity questionnaire: 12-Country reliability and
37 38	681		validity. Med Sci Sports Exerc [Internet]. 2003 [cited 2022 Jun 14];35(8):1381-
39 40 41	682		95. Available from: http://www.acsm-msse.org
42 43	683	40.	Syrjala KL, Stover AC, Yi JC, Artherholt SB, Abrams JR. Measuring social
44 45	684		activities and social function in long-term cancer survivors who received
46 47 48	685		hematopoietic stem cell transplantation. Psychooncology [Internet]. 2010 May
49 50	686		1 [cited 2022 Jun 27];19(5):462–71. Available from:
51 52	687		https://onlinelibrary.wiley.com/doi/full/10.1002/pon.1572
53 54 55	688	41.	Bastien CH, Vallières A, Morin CM. Validation of the insomnia severity index
56 57	689		as an outcome measure for insomnia research. Sleep Med. 2001 Jul
58 59 60	690		1;2(4):297–307.

Page 31 of 36

1

BMJ Open

2 3 4	691	42.	Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J
5 6 7 8	692		Health Soc Behav. 1983;24(4):385–96.
	693	43.	Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta
9 10 11	694		Psychiatr Scand [Internet]. 1983 Jun 1 [cited 2018 Apr 28];67(6):361–70.
12 13	695		Available from: http://doi.wiley.com/10.1111/j.1600-0447.1983.tb09716.x
14 15	696	44.	Osman A, Bagge CL, Gutierrez PM, Konick LC, Kopper BA, Barrios FX. The
16 17 18	697		suicidal behaviors questionnaire-revised (SBQ-R): Validation with clinical and
19 20	698		nonclinical samples. Assessment [Internet]. 2001 Jul 26 [cited 2022 Jun
21 22	699		14];8(4):443–54. Available from:
23 24 25	700		https://journals.sagepub.com/doi/abs/10.1177/107319110100800409
23 26 27 28 29 30 31 32 33 34 35 36	701	45.	Raes F, Pommier E, Neff KD, Van Gucht D. Construction and factorial
	702		validation of a short form of the Self-Compassion Scale. Clin Psychol
	703		Psychother [Internet]. 2011 May 1 [cited 2022 Jun 14];18(3):250–5. Available
	704		from: https://onlinelibrary.wiley.com/doi/full/10.1002/cpp.702
	705	46.	Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al.
37 38 20	706		Development and preliminary testing of the new five-level version of EQ-5D
39 40 41	707		(EQ-5D-5L). Qual Life Res [Internet]. 2011 Dec 9 [cited 2022 Jun
42 43	708		14];20(10):1727–36. Available from:
44 45	709		https://link.springer.com/article/10.1007/s11136-011-9903-x
46 47 48	710	47.	Carney CE, Buysse DJ, Ancoli-Israel S, Edinger JD, Krystal AD, Lichstein KL,
49 50	711		et al. The consensus sleep diary: Standardizing prospective sleep self-
51 52	712		monitoring [Internet]. Vol. 35, Sleep. Oxford Academic; 2012 [cited 2022 Jun
53 54 55	713		14]. p. 287–302. Available from:
55 56 57	714		https://academic.oup.com/sleep/article/35/2/287/2558899
58 59 60	715	48.	Ancoli-Israel S. Actigraphy. Princ Pract Sleep Med. 2005;1459–67.

Page 32 of 36

BMJ Open

32

2			
2 3 4	716	49.	Williams JM, Taylor DJ, Slavish DC, Gardner CE, Zimmerman MR, Patel K, et
5 6 7 8	717		al. Validity of Actigraphy in Young Adults With Insomnia.
7 8	718		https://doi.org/101080/1540200220181545653 [Internet]. 2018 Jan 2 [cited
9 10 11 12 13 14 15 16	719		2022 Jun 27];18(1):91–106. Available from:
	720		https://www.tandfonline.com/doi/abs/10.1080/15402002.2018.1545653
14 15	721	50.	Mccall C, Mccall WV. Comparison of actigraphy with polysomnography and
16 17 19	722		sleep logs in depressed insomniacs. J Sleep Res. 2012 Feb;21(1):122–7.
19 20	723	51.	Fekedulegn D, Andrew ME, Shi M, Violanti JM, Knox S, Innes KE. Actigraphy-
21 22	724		Based Assessment of Sleep Parameters. Ann Work Expo Heal [Internet]. 2020
23 24 25	725		Apr 30 [cited 2022 Jun 27];64(4):350–67. Available from:
25 26 27	726		https://academic.oup.com/annweh/article/64/4/350/5735350
27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43	727	52.	Ancoli-Israel S, Martin JL, Blackwell T, Buenaver L, Liu L, Meltzer LJ, et al.
	728		The SBSM Guide to Actigraphy Monitoring: Clinical and Research
	729		Applications. https://doi.org/101080/1540200220151046356 [Internet]. 2015
	730		Jul 17 [cited 2022 Jun 27];13:S4–38. Available from:
	731		https://www.tandfonline.com/doi/abs/10.1080/15402002.2015.1046356
	732	53.	Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical
42 43	733		and Powerful Approach to Multiple Testing. J R Stat Soc Ser B [Internet]. 1995
44 45	734		Jan 1 [cited 2022 Jun 28];57(1):289–300. Available from:
46 47	735		https://onlinelibrary.wiley.com/doi/full/10.1111/j.2517-6161.1995.tb02031.x
40 49 50	736	54.	Akaike H. Information Theory and an Extension of the Maximum Likelihood
51 52	737		Principle. In Springer, New York, NY; 1998 [cited 2022 Jun 27]. p. 199–213.
53 54	738		Available from: https://link.springer.com/chapter/10.1007/978-1-4612-1694-
55 56 57	739		0_15
58 59 60	740	55.	Akaike H. A New Look at the Statistical Model Identification. IEEE Trans

60

1

BMJ Open

33

2			
3 4 5 6 7 8 9	741		Automat Contr. 1974;19(6):716–23.
	742	56.	Schwarz SG. "Estimating the Dimension of a Model." Ann Stat [Internet]. 1978
	743		[cited 2022 Jun 27];6(2):461–4. Available from:
9 10 11	744		http://www.citeulike.org/user/abhishekseth/article/90008
12 13 14 15 16 17 18 19 20	745	57.	Bates D, Mächler M, Bolker BM, Walker SC. Fitting linear mixed-effects
	746		models using Ime4. J Stat Softw [Internet]. 2015 Jun 23 [cited 2022 Jun
	747		27];67(1). Available from: https://arxiv.org/abs/1406.5823v1
	748	58.	R Core Team. R: A Language and Environment for Statistical Computing.
21 22	749		Vienna R foundation for Statistical Computing.; 2012.
23 24 25	750	59.	Epskamp S, Waldorp LJ, Mõttus R, Borsboom D. The Gaussian Graphical
25 26 27	751		Model in Cross-Sectional and Time-Series Data. Multivariate Behav Res
28 29	752		[Internet]. 2018 Jul 4 [cited 2022 Jun 29];53(4):453–80. Available from:
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47	753		https://www.tandfonline.com/doi/abs/10.1080/00273171.2018.1454823
	754	60.	Bringmann LF, Vissers N, Wichers M, Geschwind N, Kuppens P, Peeters F, et
	755		al. A Network Approach to Psychopathology: New Insights into Clinical
	756		Longitudinal Data. PLoS One [Internet]. 2013 Apr 4 [cited 2022 Jun
	757		27];8(4):e60188. Available from:
	758		https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0060188
	759	61.	Matthews KA, Patel SR, Pantesco EJ, Buysse DJ, Kamarck TW, Lee L, et al.
	760		Similarities and differences in estimates of sleep duration by
48 49 50	761		polysomnography, actigraphy, diary, and self-reported habitual sleep in a
51 52	762		community sample. Sleep Heal. 2018 Feb 1;4(1):96–103.
53 54	763	12. F	
55	/64	_	
56	765	F	igure 1
5/	766	Т	he study uses a prospective experience sampling design involving in vivo data
58 59	767	g	athering using survey and actigraphy. The participants are asked to engage with
	7/0		

the data collection process over 7 consecutive days (8 nights) twice, six-months

BMJ Open

apart. An example data collection procedure in a single day is detailed in the box of dashed outline. The participants are prompted to complete a sleep diary in the morning and 3 daily surveys each day. The participants are also asked to wear an actigraph during the entire 7-day (8-night) period for each wave, generating objective estimates of sleep and physical activity. The timing of the diary and surveys is pre-specified. If a participant's typical wake time is 08:00, a prompt to complete the sleep diary will be sent at 08:30, then the first, second and third daily surveys at 11:00, 13:30 and 16:00.








COVID Checklist

The checklist is administered by a member of the research team over the telephone once per person, per timepoint (T1 and T2). This is to ensure reduced risk of virus transmission and to ensure that the sleep, pain, mood and activity measured within the study are representative of their typical chronic pain and not influenced by COVID infection. The COVID checklist requires participants to answer three questions to determine any recent exposure:

1. Have you experienced any of the main COVID-19 symptoms in the last 48 hours?

2. In the last 7 days have you come into close contact with anyone who has tested positive for COVID-19 to your knowledge?

3. Are you or is anyone in your household/bubble currently self-isolating?

If a participant answers 'yes' to one or multiple questions, they will be asked to postpone their participation until they no longer test positive. Data obtained from the checklist will not be analysed as their purposes are for health and safety and to maintain data integrity.

review only